UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q



(Mark One)
ý	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED ~~SEPTEMBER 29, 2012~~MARCH 30, 2013
OR
o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM TO

Commission File No. 001-15943

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

(Exact Name of Registrant as Specified in Its Charter)



Delaware		06-1397316
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)
251 Ballardvale Street Wilmington, Massachusetts (Address of Principal Executive Offices)		01887 (Zip Code)

(Registrant's telephone number, including area code): (781) 222-6000

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files. Yes ý No o

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.



Large accelerated filer ý	Accelerated filer o	Non-accelerated filer o (Do not check if smaller reporting company)	Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No ý

As of ~~October 19, 2012~~April 22, 2013, there were ~~48,553,049~~49,029,250 shares of the Registrant's common stock outstanding.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

FORM 10-Q

For the Quarterly Period Ended ~~September 29, 2012~~March 30, 2013

TABLE OF CONTENTS



			Page
Part I.	Financial Information
	Item 1.	Financial Statements
		Condensed Consolidated Statements of Income (Unaudited) for the three ~~and nine~~ months ended ~~September 29,~~March 30, 2013 and March 31, 2012 ~~and September 24, 2011~~	3
		Condensed Consolidated Statements of Comprehensive Income (Unaudited) for the three ~~and nine~~ months ended ~~September 29,~~March 30, 2013 and March 31, 2012 ~~and September 24, 2011~~	4
		Condensed Consolidated Balance Sheets (Unaudited) as of ~~September~~March 30, 2013 and December 29, 2012 ~~and December 31, 2011~~	5
		Condensed Consolidated Statements of Cash Flows (Unaudited) for the ~~nine~~three months ended ~~September 29,~~March 30, 2013 and March 31, 2012 ~~and September 24, 2011~~	6
		Condensed Consolidated Statement of Changes in Equity (Unaudited) for the ~~nine~~three months ended ~~September 29, 2012~~March 30, 2013	7
		Notes to Condensed Consolidated Interim Financial Statements	8
	Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	2625
	Item 3.	Quantitative and Qualitative Disclosure About Market Risk	3329
	Item 4.	Controls and Procedures	3430
Part II.	Other Information
	Item 1A.	Risk Factors	3431
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	3431
	Item 6.	Exhibits	3633

Special Note on Factors Affecting Future Results

This Quarterly Report on Form 10-Q contains forward‑looking statements regarding future events and the future results of Charles River Laboratories International, Inc. (Charles River or ~~We)~~we) that are based on our current expectations, estimates, forecasts, and projections about the industries in which ~~Charles River~~we operates and the beliefs and assumptions of our management. Words such as “expect,” “anticipate,” “target,” “goal,” “project,” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “likely,” “may,” “designed,” “would,” “future,” “can,” “could” and other similar expressions that are predictions of or indicate future events and trends or which do not relate to historical matters are intended to identify such forward‑looking statements. These statements are based on our current expectations and beliefs and involve a number of risks, uncertainties, and assumptions that are difficult to predict. For example, we may use forward‑looking statements when addressing topics such as: the pursuit of our initiatives to optimize returns for stockholders, including efforts to improve our operating margins, improve free cash flow, invest in growth businesses and return value to shareholders; future demand for drug discovery and development products and services, including the outsourcing of these services and spending trends by our ~~customers;~~clients; our expectations regarding stock ~~repurchases;~~repurchases, including the number of shares to be repurchased, expected timing and duration, the amount of capital that may be expended and the treatment of repurchased shares; present spending trends and other cost reduction activities by our ~~customers;~~clients; future actions by our management; the outcome of contingencies; changes in our business strategy; changes in our business practices and methods of generating revenue; the development and performance of our services and products; market and industry conditions, including competitive and pricing trends; our strategic relationships with leading pharmaceutical companies and opportunities for future similar arrangements; changes in the composition or level of our revenues; our cost structure; the impact of acquisitions and dispositions; our expectations with respect to sales growth and operating synergies (including the impact of specific actions intended to cause related improvements); the impact of specific actions intended to improve overall operating efficiencies and profitability (and our ability to accommodate future demand with our infrastructure); changes in our expectations regarding future stock option, restricted stock, and other equity grants to employees and directors; expectations with respect to foreign currency exchange; assessing (or changing our assessment of) our tax positions for financial statement purposes; and our cash flow and liquidity. In addition, these statements include the impact of economic and market conditions on our ~~customers;~~clients; the effects of our cost-saving actions and the steps to optimize returns to shareholders on an effective and timely basis and the ability of Charles River to withstand the current market conditions. You should not rely on forward‑looking statements because they are predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed in any forward‑looking statements. You are cautioned not to place undue reliance on these forward‑looking statements, which speak only as of the date of this document or in the case of statements incorporated by reference, on the date of the document incorporated by reference. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in our Annual Report on Form 10-K for the year ended December ~~31, 2011~~29, 2012 under the section entitled “Our Strategy,” the section entitled “Risks Related to Our Business and Industry,” the section entitled “Management's Discussion and Analysis of Financial Condition and Results of Operations” and in our press releases and other financial filings with the Securities and Exchange Commission. We have no obligation to publicly update or revise any forward‑looking statements, whether as a result of new information, future events or risks. New information, future events or risks may cause the forward‑looking events we discuss in this report not to occur.

Part I. Financial Information

Item 1. Financial Statements

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)

(dollars in thousands, except per share amounts)


	Three Months Ended						Nine Months Ended						Three Months Ended
	September 29, 2012			September 24, 2011			September 29, 2012			September 24, 2011			March 30, 2013			March 31, 2012
Net sales related to products	$	111,196		$	116,932		$	356,535		$	361,069		$	126,287		$	126,214
Net sales related to services	167,490			160,647			492,855			490,616			164,951			159,767
Net sales	278,686			277,579			849,390			851,685			291,238			285,981
Costs and expenses
Cost of products sold	63,649			66,368			190,629			197,405			66,033			64,945
Cost of services provided	121,778			118,495			357,705			352,606			120,994			116,824
Selling, general and administrative	51,047			50,345			156,924			152,561			57,199			55,977
Amortization of other intangibles	4,530			5,277			13,436			16,454			4,249			4,495
Operating income	37,682			37,094			130,696			132,659			42,763			43,740
Other income (expense)
Interest income	124			138			460			1,060			97			185
Interest expense	(8,519		)	(11,944		)	(25,033		)	(32,619		)	(8,280		)	(8,435		)
Other, net	(892		)	(747		)	(2,582		)	(1,092		)	1,068			(344		)
Income from continuing operations, before income taxes	28,395			24,541			103,541			100,008			35,648			35,146
Provision for income taxes	6,011			5,630			24,140			11,564			9,722			8,676
Income from continuing operations, net of income taxes	22,384			18,911			79,401			88,444			25,926			26,470
Loss from discontinued operations, net of taxes	(182		)	(18		)	(63		)	(5,695		)
Income (loss) from discontinued operations, net of taxes													(155		)	77
Net income	22,202			18,893			79,338			82,749			25,771			26,547
Less: Net income attributable to noncontrolling interests	(230		)	(95		)	(459		)	(298		)	(193		)	(108		)
Net income attributable to common shareowners	$	21,972		$	18,798		$	78,879		$	82,451		$	25,578		$	26,439
Earnings (loss) per common share
Earnings per common share
Basic:
Continuing operations attributable to common shareowners	$	0.47		$	0.38		$	1.64		$	1.71		$	0.54		$	0.55
Discontinued operations	$	—		$	—		$	—		$	(0.11	)	$	—		$	—
Net income attributable to common shareowners	$	0.46		$	0.38		$	1.64		$	1.60		$	0.54		$	0.55
Diluted:
Continuing operations attributable to common shareowners	$	0.46		$	0.37		$	1.63		$	1.69		$	0.53		$	0.54
Discontinued operations	$	—		$	—		$	—		$	(0.11	)	$	—		$	—
Net income attributable to common shareowners	$	0.46		$	0.37		$	1.63		$	1.58		$	0.53		$	0.54

See Notes to Condensed Consolidated Interim Financial Statements.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)

(dollars in thousands, except per share amounts)


	Three Months Ended						Nine Months Ended
	September 29, 2012			September 24, 2011			September 29, 2012			September 24, 2011			March 30, 2013			March 31, 2012
Net income	$	22,202		$	18,893		$	79,338		$	82,749		$	25,771		$	26,547
Foreign currency translation adjustment	12,962			(12,643		)	8,871			(6,943		)	(19,933		)	6,780
Unrealized gains (losses) on marketable securities:
Unrealized gains (losses) for the period	—			(168		)	209			(305		)	—			209
Add: reclassification adjustment for losses included in net income	—			—			712			—			—			712
Defined benefit plan gains (losses) and prior service costs not yet recognized as components of net periodic pension cost:
Amortization of prior service costs and net gains and losses	560			260			1,880			759
Amortization of prior service costs and net gains and losses (Note 10)													737			661
Comprehensive income, before tax	35,724			6,342			91,010			76,260			6,575			34,909
Income tax expense related to items of other comprehensive income	156			572			701			1,111			904			261
Comprehensive income, net of tax	35,568			5,770			90,309			75,149			5,671			34,648
Less: comprehensive income related to noncontrolling interests	(225		)	(121		)	(459		)	(354		)	(229		)	(126		)
Comprehensive income attributable to common shareholders	$	35,343		$	5,649		$	89,850		$	74,795		$	5,442		$	34,522

See Notes to Condensed Consolidated Interim Financial Statements.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(dollars in thousands, except per share amounts)


	September 29, 2012			December 31, 2011			March 30, 2013			December 29, 2012
Assets
Current assets
Cash and cash equivalents	$	83,224		$	68,905		$	100,422		$	109,685
Trade receivables, net	215,621			184,810			213,540			203,001
Inventories	93,718			92,969			84,959			88,470
Other current assets	65,243			79,052			92,993			83,601
Current assets of discontinued businesses	109			107			705			495
Total current assets	457,915			425,843			492,619			485,252
Property, plant and equipment, net	724,699			738,030			707,053			717,020
Goodwill, net	207,420			197,561			227,082			208,609
Other intangibles, net	89,777			93,437			95,035			84,922
Deferred tax asset	45,917			44,804			29,857			38,554
Other assets	40,987			57,659			48,985			48,659
Long-term assets of discontinued businesses	903			986			3,177			3,328
Total assets	$	1,567,618		$	1,558,320		$	1,603,808		$	1,586,344
Liabilities and Equity
Current liabilities
Current portion of long-term debt and capital leases	$	125,603		$	14,758		$	130,851		$	139,384
Accounts payable	27,744			34,332			31,277			31,218
Accrued compensation	48,771			41,602			43,620			46,951
Deferred revenue	57,833			56,530			53,187			56,422
Accrued liabilities	49,655			54,377			48,078			45,208
Other current liabilities	14,539			14,033			21,166			21,262
Current liabilities of discontinued businesses	1,092			1,165			2,633			1,802
Total current liabilities	325,237			216,797			330,812			342,247
Long-term debt and capital leases	543,143			703,187			518,035			527,136
Other long-term liabilities	96,975			108,451			106,969			104,966
Long-term liabilities of discontinued businesses	2,311			2,522			8,126			8,795
Total liabilities	967,666			1,030,957			963,942			983,144
Commitments and contingencies
Redeemable noncontrolling interest							9,038			—
Shareowners' equity
Preferred stock, $0.01 par value; 20,000,000 shares authorized; no shares issued and outstanding	—			—			—			—
Common stock, $0.01 par value; 120,000,000 shares authorized; 79,385,168 issued and 48,480,525 shares outstanding at September 29, 2012 and 78,473,888 issued and 48,875,715 shares outstanding at December 31, 2011	794			785
Common stock, $0.01 par value; 120,000,000 shares authorized; 80,763,440 issued and 49,106,698 shares outstanding at March 30, 2013 and 79,607,981 issued and 48,220,037 shares outstanding at December 29, 2012							807			796
Capital in excess of par value	2,085,034			2,056,921			2,130,266			2,097,316
Accumulated deficit	(386,717		)	(465,596		)	(342,723		)	(368,301		)
Treasury stock, at cost, 30,904,643 shares and 29,598,173 shares at September 29, 2012 and December 31, 2011, respectively	(1,116,962		)	(1,071,120		)
Treasury stock, at cost, 31,656,742 shares and 31,387,944 shares at March 30, 2013 and December 29, 2012, respectively							(1,146,538		)	(1,135,609		)
Accumulated other comprehensive income	15,564			4,593			(13,533		)	6,603
Total shareowners' equity	597,713			525,583			628,279			600,805
Noncontrolling interests	2,239			1,780			2,549			2,395
Total equity	599,952			527,363			639,866			603,200
Total liabilities and equity	$	1,567,618		$	1,558,320		$	1,603,808		$	1,586,344

See Notes to Condensed Consolidated Interim Financial Statements.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(dollars in thousands)


	Nine Months Ended						Three Months Ended
	September 29, 2012			September 24, 2011			March 30, 2013			March 31, 2012
Cash flows relating to operating activities
Net income	$	79,338		$	82,749		$	25,771		$	26,547
Less: Income (loss) from discontinued operations	(63		)	(5,695		)	(155		)	77
Income from continuing operations	79,401			88,444			25,926			26,470
Adjustments to reconcile net income from continuing operations to net cash provided by operating activities:
Depreciation and amortization	60,617			64,249			20,010			20,002
Amortization of debt issuance costs and discounts	13,136			15,229			4,557			4,345
Non-cash compensation	15,828			16,919			5,904			5,266
Deferred income taxes	(1,338		)	(1,460		)	6,734			5,740
Other, net	7,493			110			772			1,535
Changes in assets and liabilities:
Trade receivables	(27,931		)	(8,467		)	(14,234		)	(19,881		)
Inventories	(2,183		)	7,090			2,922			3,312
Other assets	1,201			1,834			(4,775		)	(462		)
Accounts payable	(6,743		)	459			(5,038		)	(2,187		)
Accrued compensation	6,287			(5,143		)	(2,651		)	(1,659		)
Deferred revenue	283			(12,400		)	(3,888		)	963
Accrued liabilities	(1,518		)	(3,730		)	1,827			(5,114		)
Taxes payable and prepaid taxes	7,323			(21,196		)	(6,938		)	(7,320		)
Other liabilities	(8,177		)	(6,993		)	(1,151		)	(5,733		)
Net cash provided by operating activities	143,679			134,945			29,977			25,277
Cash flows relating to investing activities
Acquisition of business, less cash acquired	(16,902		)	—
Acquisition of businesses, net of cash acquired							(24,141		)	—
Capital expenditures	(33,795		)	(21,672		)	(6,429		)	(14,112		)
Purchases of investments	(10,814		)	(19,837		)	(3,847		)	(4,694		)
Proceeds from sale of investments	23,549			27,840			5,589			14,555
Other, net	2,746			1,620			46			973
Net cash used in investing activities	(35,216		)	(12,049		)	(28,782		)	(3,278		)
Cash flows relating to financing activities
Proceeds from long-term debt and revolving credit agreement	53,115			235,806			32,803			28,000
Proceeds from exercises of stock options and warrants	11,916			20,574			25,148			2,715
Payments on long-term debt, capital lease obligation and revolving credit agreement	(112,731		)	(214,299		)	(54,902		)	(46,566		)
Purchase of treasury stock and Accelerated Stock Repurchase Program	(45,842		)	(255,610		)
Purchase of treasury stock							(11,229		)	(15,246		)
Other, net	535			(2,248		)	1,670			462
Net cash used in financing activities	(93,007		)	(215,777		)	(6,510		)	(30,635		)
Discontinued operations
Net cash used in operating activities	(292		)	(1,703		)	(3		)	—
Net cash used in discontinued operations	(292		)	(1,703		)
Net cash provided by discontinued operations							(3		)	—
Effect of exchange rate changes on cash and cash equivalents	(845		)	(3,356		)	(3,945		)	762
Net change in cash and cash equivalents	14,319			(97,940		)	(9,263		)	(7,874		)
Cash and cash equivalents, beginning of period	68,905			179,160			109,685			68,905
Cash and cash equivalents, end of period	$	83,224		$	81,220		$	100,422		$	61,031
Supplemental cash flow information
Capitalized interest	$	472		$	202		$	64		$	191

See Notes to Condensed Consolidated Interim Financial Statements.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (UNAUDITED)

(dollars in thousands)


	Total			Accumulated (Deficit) Earnings			Accumulated Other Comprehensive Income		Common Stock		Capital in Excess of Par			Treasury Stock			Non-controlling Interest		Total			Accumulated (Deficit) Earnings			Accumulated Other Comprehensive Income			Common Stock		Capital in Excess of Par		Treasury Stock			Non-controlling Interests
December 31, 2011	$	527,363		$	(465,596	)	$	4,593	$	785	$	2,056,921		$	(1,071,120	)	$	1,780
December 29, 2012																			$	603,200		$	(368,301	)	$	6,603		$	796	$	2,097,316	$	(1,135,609	)	$	2,395
Components of comprehensive income, net of tax:
Net income	79,338			78,879													459		25,771			25,578													193
Other comprehensive income	10,971						10,971										—
Other comprehensive loss																			(20,100		)				(20,136		)								36
Total comprehensive income	90,309																459		5,671																229
Tax detriment associated with stock issued under employee compensation plans	(10		)								(10		)
Redeemable noncontrolling interest acquired in business combination																			8,963																8,963
Tax benefit associated with stock issued under employee compensation plans																			1,794											1,794
Issuance of stock under employee compensation plans	12,304								9		12,295								25,263									11		25,252
Acquisition of treasury shares	(45,842		)								—			(45,842		)			(10,929		)									—		(10,929		)
Stock-based compensation	15,828										15,828								5,904											5,904
September 29, 2012	$	599,952		$	(386,717	)	$	15,564	$	794	$	2,085,034		$	(1,116,962	)	$	2,239
March 30, 2013																			$	639,866		$	(342,723	)	$	(13,533	)	$	807	$	2,130,266	$	(1,146,538	)	$	11,587

See Notes to Condensed Consolidated Interim Financial Statements.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(dollars in thousands, except per share amounts)


1.	BASIS OF PRESENTATION

The condensed consolidated interim financial statements are unaudited, and certain information and footnote disclosures related thereto normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America have been omitted in accordance with Rule 10-01 of Regulation S-X. In the opinion of management, the accompanying unaudited condensed consolidated financial statements were prepared following the same policies and procedures used in the preparation of the audited financial statements and reflect all adjustments (consisting of normal recurring adjustments) considered necessary to state fairly the financial position and results of operations of Charles River Laboratories International, Inc. The results of operations for the interim periods are not necessarily indicative of the results for the entire fiscal year. These condensed consolidated financial statements should be read in conjunction with our Annual Report on Form 10-K for the year ended December ~~31, 2011.~~

29, 2012~~Certain amounts in prior-year financial statements and related notes have been reclassified to conform with the current year presentation. For a summary of recent accounting pronouncements, please see"Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations", page 33.~~.

2. RESTRUCTURING ~~AND CONTRACT TERMINATION~~ COSTS

~~In September 2012, we commenced a consolidation of certain research model operations in Europe. As a result, we recorded an impairment charge of~~ ~~$3,548~~ ~~for the disposition of facilities that we own. The assets will be classified as held-for-use as we unwind operations over the next several months. In addition, we~~We have implemented staffing reductions ~~associated with~~over the ~~affected operations~~past few years to improve operating efficiency and ~~accordingly, we recorded severance and retention charges of~~ ~~$865~~ ~~for the three months ended September 29, 2012.~~profitability at various sites. As a result of these actions, for the three months ended March 30, 2013and ~~previously implemented staffing reductions,~~March 31, 2012, we recorded severance and retention charges as shown below. As of ~~September 29, 2012~~March 30, 2013, $~~1,946~~1,791 was included in accrued compensation and $~~1,894~~1,644 in other long-term liabilities on our consolidated balance sheet.

The following table rolls forward our severance and retention cost liability:


	Nine Months Ended						Three Months Ended
	September 29, 2012			September 24, 2011			March 30, 2013			March 31, 2012
Balance, beginning of period	$	3,374		$	10,658		$	3,636		$	3,374
Expense	1,881			1,317			297			911
Payments/utilization	(1,415		)	(7,625		)	(498		)	(608		)
Balance, end of period	$	3,840		$	4,350		$	3,435		$	3,677

The following table presents severance and retention costs by classification on the income statement:


	Nine Months Ended				Three Months Ended
	September 29, 2012		September 24, 2011		March 30, 2013		March 31, 2012
Severance charges included in cost of sales	$	936	$	437	$	227	$	—
Severance charges included in selling, general and administrative expense	945		880		70		911
Total expense	$	1,881	$	1,317	$	297	$	911

The following table presents severance and retention cost by segment:



	Three Months Ended
	March 30, 2013		March 31, 2012
Research models and services	$	86	$	—
Preclinical services	211		911
Corporate	—		—
Total expense	$	297	$	911

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Continued)

(dollars in thousands, except per share amounts)

~~The following table presents severance and retention cost by segment:~~

Nine Months Ended
September 29, 2012 September 24, 2011
Research models and services $ 934
$ 444
Preclinical services 947
979
Corporate —
(106 )
Total expense $ 1,881
$ 1,317

3. SUPPLEMENTAL BALANCE SHEET INFORMATION

The composition of net trade receivables is as follows:


	September 29, 2012			December 31, 2011			March 30, 2013			December 29, 2012
Client receivables	$	188,203		$	159,381		$	183,362		$	174,774
Unbilled revenue	31,301			29,446			34,674			32,494
Total	219,504			188,827			218,036			207,268
Less allowance for doubtful accounts	(3,883		)	(4,017		)	(4,496		)	(4,267		)
Net trade receivables	$	215,621		$	184,810		$	213,540		$	203,001

The composition of inventories is as follows:


	September 29, 2012		December 31, 2011		March 30, 2013		December 29, 2012
Raw materials and supplies	$	13,352	$	13,987	$	13,952	$	14,525
Work in process	14,203		13,533		10,309		11,082
Finished products	66,163		65,449		60,698		62,863
Inventories	$	93,718	$	92,969	$	84,959	$	88,470

The composition of other current assets is as follows:


	September 29, 2012		December 31, 2011		March 30, 2013		December 29, 2012
Prepaid assets	$	22,016	$	22,828	$	24,033	$	20,404
Deferred tax asset	25,220		30,894		30,477		30,018
Marketable securities	6,352		5,359		6,846		6,781
Prepaid income tax	11,426		19,742		31,408		26,169
Restricted cash	229		229		229		229
Other current assets	$	65,243	$	79,052	$	92,993	$	83,601

The composition of net property, plant and equipment is as follows:



	March 30, 2013			December 29, 2012
Land	$	40,344		$	40,812
Buildings	687,309			697,547
Machinery and equipment	356,629			356,960
Leasehold improvements	35,542			34,916
Furniture and fixtures	24,766			25,681
Vehicles	3,848			3,736
Computer hardware and software	109,374			107,171
Construction in progress	46,320			46,186
Total	1,304,132			1,313,009
Less accumulated depreciation	(597,079		)	(595,989		)
Net property, plant and equipment	$	707,053		$	717,020

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Continued)

(dollars in thousands, except per share amounts)

~~The composition of net property, plant and equipment is as follows:~~

September 29, 2012 December 31, 2011
Land $ 41,240
$ 40,517
Buildings 707,897
696,275
Machinery and equipment 351,125
332,683
Leasehold improvements 35,427
29,975
Furniture and fixtures 26,840
26,775
Vehicles 3,668
5,226
Computer hardware and software 107,025
105,563
Construction in progress 43,362
57,661
Total 1,316,584
1,294,675
Less accumulated depreciation (591,885 ) (556,645 )
Net property, plant and equipment $ 724,699
$ 738,030

Depreciation is calculated for financial reporting purposes using the straight-line method based on the estimated useful lives of the assets. Depreciation expense for the quarter ended ~~nine months endedSeptember 29, 2012~~March 30, 2013 and ~~September 24, 2011~~March 31, 2012 was $~~47,181~~15,761 and $~~47,795~~15,507, respectively.

The composition of other assets is as follows:


	September 29, 2012		December 31, 2011		March 30, 2013		December 29, 2012
Deferred financing costs	$	7,080	$	9,239	$	5,696	$	6,424
Cash surrender value of life insurance policies	20,501		25,057		24,316		25,240
Long term marketable securities	—		11,051
Equity-method affiliates					8,402		8,492
Other assets	13,406		12,312		10,571		8,503
Other assets	$	40,987	$	57,659	$	48,985	$	48,659

The composition of other current liabilities is as follows:


	September 29, 2012		December 31, 2011		March 30, 2013		December 29, 2012
Accrued income taxes	$	8,968	$	10,552	$	16,084	$	18,216
Current deferred tax liability	1,115		1,379		418		410
Accrued interest and other	4,456		2,102		4,664		2,636
Other current liabilities	$	14,539	$	14,033	$	21,166	$	21,262

The composition of other long-term liabilities is as follows:



	March 30, 2013		December 29, 2012
Deferred tax liability	$	16,163	$	13,147
Long-term pension liability	41,417		44,316
Accrued Executive Supplemental Life Insurance Retirement Plan and Deferred Compensation Plan	28,211		26,663
Other long-term liabilities	21,178		20,840
Other long-term liabilities	$	106,969	$	104,966

4. MARKETABLE SECURITIES AND EQUITY-METHOD AFFILIATES

Investments in marketable securities are reported at fair value and consist of time deposits. The fair value for these time deposits approximate fair value. The amortized cost, gross unrealized gains, gross unrealized losses and fair value for marketable securities by major security type were as follows:



	March 30, 2013
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Time deposits	$	6,846	$	—	$	—	$	6,846
	$	6,846	$	—	$	—	$	6,846

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Continued)

(dollars in thousands, except per share amounts)

~~The composition of other long-term liabilities is as follows:~~

September 29, 2012 December 31, 2011
Deferred tax liability $ 14,268
$ 16,074
Long-term pension liability 39,383
49,223
Accrued Executive Supplemental Life Insurance Retirement Plan and Deferred Compensation Plan 26,309
25,739
Other long-term liabilities 17,015
17,415
Other long-term liabilities $ 96,975
$ 108,451

~~4. MARKETABLE SECURITIES AND EQUITY METHOD AFFILIATES~~

~~Investments in marketable securities are reported at fair value and consist of time deposits and auction rate securities. During the~~ ~~nine months endedSeptember 29, 2012, we sold our auction rate securities for~~ ~~$11,260~~ ~~in cash and recorded a realized loss of~~ ~~$712~~ ~~, which is included in other income (expense).~~

~~The amortized cost, gross unrealized gains, gross unrealized losses and fair value for marketable securities by major security type were as follows:~~

September 29, 2012

Amortized
Cost

Gross
Unrealized
Gains

Gross
Unrealized
Losses

Fair
Value
Time deposits $ 6,352
$ —
$ —
$ 6,352
Auction rate securities —
—
—
—
$ 6,352
$ —
$ —
$ 6,352

December 31, 2011

Amortized
Cost

Gross
Unrealized
Gains

Gross
Unrealized
Losses

Fair
Value
Time deposits $ 5,359
$ —
$ —
$ 5,359
Auction rate securities 11,972
—
(921 ) 11,051
$ 17,331
$ —
$ (921 ) $ 16,410



	December 29, 2012
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Time deposits	$	6,781	$	—	$	—	$	6,781
	$	6,781	$	—	$	—	$	6,781

Maturities of debt securities were as follows:


	September 29, 2012				December 31, 2011				March 30, 2013				December 29, 2012
	Amortized Cost		Fair Value		Amortized Cost		Fair Value		Amortized Cost		Fair Value		Amortized Cost		Fair Value
Due less than one year	$	6,352	$	6,352	$	5,359	$	5,359	$	6,846	$	6,846	$	6,781	$	6,781
Due after one year through five years	—		—		—		—		—		—		—		—
Due after ten years	—		—		11,972		11,051		—		—		—		—
	$	6,352	$	6,352	$	17,331	$	16,410	$	6,846	$	6,846	$	6,781	$	6,781

Equity-Method Affiliates

In 2009, we entered into a limited partnership, which invests in biotechnology and medical device companies. We committed $20,000, or approximately 12%, of the limited partnership's total committed capital. As of ~~September 29, 2012~~March 30, 2013, we have contributed $~~7,920~~8,820 of our total committed capital of $20,000. We recognized equity ~~losses~~loss of $~~380~~ ~~and~~ ~~$245~~90 for the three ~~and~~months ended ~~nine months endedSeptember 29, 2012~~March 30, 2013~~, respectively. These losses are~~. This loss is reported aswithin other income (expense). As of

~~CHARLES RIVER LABORATORIES INTERNATIONAL, INC.~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Continued)~~

~~(dollars in thousands, except per share amounts)~~

~~September 29, 2012~~March 30, 2013, ~~equity method affiliates~~Equity Method Affiliates had a carrying value of $~~7,965~~8,402, which is reported in other assets on the consolidated balance sheets.

During the first quarter of 2013, we entered into another limited partnership, which invests in technology and life sciences companies with an emphasis on early stage investments. We committed $10,000 to the limited partnership. As of March 30, 2013, no contributions have been made to the limited partnership.

5. FAIR VALUE

Valuation methodologies used for assets and liabilities measured or disclosed at fair value are as follows:

Time deposits—Valued at their ending balances as reported by the financial institutions that hold our securities, which approximates fair value.

Auction rate securities—Valued at fair value by management in part utilizing an independent valuation using pricing models and discounted cash flow methodologies incorporating assumptions that reflect the assumptions a marketplace participant would use.

Life policies—Valued at cash surrender ~~value.~~value based on fair value of underlying investments.

Hedge contract—Valued at fair value by management based on our foreign exchange rates and forward points provided by banks.

~~Long-lived assets impaired during~~

Redeemable noncontrolling interest—Valued based on actual and projected financial data and market multiples for similar business acquisition transactions. For the ~~period—Valued~~quarter ended March 30, 2013, management considered the recent purchase price paid for 75% of Vital River of $26,890 in January 2013 to calculate the fair value of the 25% not owned by the Company (i.e. the redeemable noncontrolling interest). Management considered the length of time elapsed since the acquisition in arriving at fair ~~value by management based the income approach~~value.

Long-term debt—Disclosed fair ~~value~~valued based on current market pricing for similar debt.

~~Assets and liabilities measured at fair value on a recurring basis are summarized below:~~

Fair Value Measurements at September 29, 2012 using
Quoted Prices in Active Markets for Identical Assets Level 1 Significant Other Observable Inputs Level 2 Significant Unobservable Inputs Level 3 Assets and Liabilities at Fair Value
Time deposits $ —
$ 6,352
$ —
$ 6,352
Auction rate securities —
—
—
—
Life policies —
14,865
—
14,865
Hedge contract —
(4 ) —
(4 )
Total assets measured at fair value $ —
$ 21,213
$ —
$ 21,213
Total liabilities measured at fair value $ —
$ —
$ —
$ —

Fair Value Measurements at December 31, 2011 using
Quoted Prices in Active Markets for Identical Assets Level 1 Significant Other Observable Inputs Level 2 Significant Unobservable Inputs Level 3 Assets and Liabilities at Fair Value
Time deposits $ —
$ 5,359
$ —
$ 5,359
Auction rate securities —
—
11,051
11,051
Life policies —
19,520
—
19,520
Hedge contract —
5
—
5
Total assets measured at fair value $ —
$ 24,884
$ 11,051
$ 35,935
Total liabilities measured at fair value $ —
$ —
$ —
$ —

During the quarter ended September 29, 2012, we recorded an impairment charge for long-lived assets held and used (see Note 2). As a result, we adjusted the carrying amount of this asset group, consisting of land, buildings, and equipment, to fair value, which was based on the income approach. In applying the income approach, we estimated the future net cash flows associated with operating the asset group and the asset group's salvage value. The fair value of the asset group was adjusted to ~~$1,611. We classified the fair value of this asset group as Level 3, whereby the inputs are based on management's internal estimates and not corroborated with observable market data.~~

1211

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Continued)

(dollars in thousands, except per share amounts)

Assets and liabilities measured at fair value on a recurring basis are summarized below:



	Fair Value Measurements at March 30, 2013
	Quoted Prices in Active Markets for Identical Assets Level 1		Significant Other Observable Inputs Level 2		Significant Unobservable Inputs Level 3		Assets and Liabilities at Fair Value
Time deposits	$	—	$	6,846	$	—	$	6,846
Life policies	—		18,599		—		18,599
Total assets measured at fair value	$	—	$	25,445	$	—	$	25,445
Redeemable noncontrolling interest	—		—		9,038		9,038
Total liabilities measured at fair value	$	—	$	—	$	9,038	$	9,038



	Fair Value Measurements at December 29, 2012
	Quoted Prices in Active Markets for Identical Assets Level 1		Significant Other Observable Inputs Level 2		Significant Unobservable Inputs Level 3		Assets and Liabilities at Fair Value
Time deposits	$	—	$	6,781	$	—	$	6,781
Life policies	—		19,555		—		19,555
Hedge contract	—		16		—		16
Total assets measured at fair value	$	—	$	26,352	$	—	$	26,352
Redeemable noncontrolling interest	—		—		—		—
Total liabilities measured at fair value	$	—	$	—	$	—	$	—

The book value of our term and revolving loans, which are variable rate loans carried at amortized cost, approximates fair value based current market pricing of similar debt. The fair value of our 2.25% Senior Convertible Debentures (2013 Notes), which are carried at cost less unamortized discount on our consolidated balance sheets, was $~~353,915~~353,145 as of ~~September 29, 2012~~March 30, 2013. We determine the fair value of these 2013 Notes based on their most recent quoted market price and by reference to the market value of similar debt instruments. We classify the fair value of our debt as Level 2 (significant other observable inputs) on the valuation hierarchy, where Level 2 inputs include quoted prices for similar assets and liabilities in active markets and/or quoted prices for identical or similar assets and liabilities in markets that are not active.

The following ~~table presents~~tables present a reconciliation for all assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) ~~for~~during the quarter ended ~~nine months endedSeptember 29, 2012~~March 30, 2013 and ~~September 24, 2011~~March 31, 2012. As noted in Note 15, we adjust the carrying value of the redeemable noncontrolling interest balance related to our acquisition of Vital River to fair value each quarter. We use valuation techniques that consider internal financial data, market information, and other data.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Continued)

(dollars in thousands, except per share amounts)



	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	Three Months Ended
Redeemable Noncontrolling Interest (Liability)	March 30, 2013		March 31, 2012
Beginning balance	$	—	$	—
Transfers in and/or out of Level 3	—		—
Total gains or losses (realized/unrealized):
Included in other income (expense)	38		—
Included in other comprehensive income	37		—
Purchases, issuances and settlements	8,963		—
Ending balance	$	9,038	$	—


	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)						Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	Nine Months Ended						Three Months Ended
Auction rate securities	September 29, 2012			September 24, 2011
Auction rate securities (Asset)							March 30, 2013		March 31, 2012
Beginning balance	$	11,051		$	11,377		$	—	$	11,051
Transfers in and/or out of Level 3	—			—			—		—
Total gains or losses (realized/unrealized):
Included in other income (expense)	(712		)	(1		)	—		(712		)
Included in other comprehensive income	921			(306		)	—		921
Purchases, issuances and settlements	(11,260		)	—			—		(11,260		)
Ending balance	$	—		$	11,070		$	—	$	—

We enter into derivative instruments to hedge foreign currency exchange risk to reduce the impact of changes to foreign currency rates on our financial statements. During the ~~nine months~~quarter ended ~~September 29, 2012~~March 30, 2013, we recognized $~~1,449~~233 of hedge ~~losses~~gains associated with forward currency ~~contracts.~~contracts open during the quarter. As of ~~September 29, 2012~~March 30, 2013, there were no outstanding forward currency ~~contracts had a fair value of~~ ~~$(4)~~.contracts.

6. GOODWILL AND OTHER INTANGIBLE ASSETS

As of March 30, 2013 and December 29, 2012 , other intangible assets, net, consisted of $3,438 and $3,438 of indefinite-lived intangible assets, respectively.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Continued)

(dollars in thousands, except per share amounts)

~~6. GOODWILL AND OTHER INTANGIBLE ASSETS~~

The following table displays ~~goodwill~~the gross carrying amount and ~~other~~accumulated amortization of definite-lived intangible assets ~~not subject to amortization and other intangible assets that continue to be subject to amortization:~~by major class:


	September 29, 2012					December 31, 2011					March 30, 2013					December 29, 2012
	Gross Carrying Amount		Accumulated Amortization & Impairment Loss			Gross Carrying Amount		Accumulated Amortization & Impairment Loss			Gross Carrying Amount		Accumulated Amortization & Impairment Loss			Gross Carrying Amount		Accumulated Amortization & Impairment Loss
Goodwill	$	1,224,136	$	(1,016,716	)	$	1,214,285	$	(1,016,724	)
Other intangible assets not subject to amortization:
Research models	$	3,438	$	—		$	3,438	$	—
Other intangible assets subject to amortization:
Backlog	2,848		(2,334		)	2,856		(2,253		)	$	2,839	$	(2,380	)	$	2,875	$	(2,375	)
Client relationships	307,671		(229,660		)	298,813		(210,816		)	311,606		(229,207		)	305,178		(231,902		)
Client contracts											14,547		(14,547		)	15,366		(15,366		)
Trademarks and trade names	5,320		(4,782		)	5,022		(4,706		)	5,368		(4,855		)	5,326		(4,821		)
Standard operating procedures											2,749		(1,019		)	2,751		(863		)
Other identifiable intangible assets	11,809		(4,533		)	5,415		(4,332		)	10,275		(3,779		)	10,033		(4,718		)
Total other intangible assets	$	331,086	$	(241,309	)	$	315,544	$	(222,107	)	$	347,384	$	(255,787	)	$	341,529	$	(260,045	)

The changes in the gross carrying amount and accumulated ~~amortization~~impairment loss of goodwill are as follows:


				Adjustments to Goodwill											Adjustments to Goodwill
	December 31, 2011			Acquisitions		Foreign Exchange/ Impairment			September 29, 2012			December 29, 2012			Acquisitions		Foreign Exchange			March 30, 2013
Research Models and Services
Gross carrying amount	$	56,402		$	10,520	$	(73	)	$	66,849		$	63,139		$	19,687	$	(181	)	$	82,645
Accumulated amortization	(3,721		)	—		8			(3,713		)
Preclinical Services
Gross carrying amount	1,157,883			—		(596		)	1,157,287			1,150,470			—		(1,033		)	1,149,437
Accumulated impairment loss	(1,005,000		)	—		—			(1,005,000		)	(1,005,000		)						(1,005,000		)
Accumulated amortization	(8,003		)	—		—			(8,003		)
Total
Gross carrying amount	$	1,214,285		$	10,520	$	(669	)	$	1,224,136		$	1,213,609		$	19,687	$	(1,214	)	$	1,232,082
Accumulated impairment loss	(1,005,000		)	—		—			(1,005,000		)	(1,005,000		)						(1,005,000		)
Accumulated amortization	(11,724		)	—		8			(11,716		)
Goodwill, net												$	208,609							$	227,082

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Continued)

(dollars in thousands, except per share amounts)

7. LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS

Long-Term Debt

Long-term debt consists of the following:


	September 29, 2012			December 31, 2011			March 30, 2013			December 29, 2012
2.25% Senior convertible debentures:
Principal	$	349,995		$	349,995		$	349,995		$	349,995
Unamortized debt discount	(10,556		)	(21,533		)	(2,897		)	(6,726		)
Net carrying amount of senior convertible debentures	339,439			328,462			347,098			343,269
Term loan facilities	298,069			356,322			269,775			290,947
Revolving credit facility	31,000			33,000			31,000			32,000
Other long-term debt represents secured and unsecured promissory notes, interest rates ranging from 0% to 0.5% at both September 29, 2012 and December 31, 2011, maturing between 2012 and 2013	226			118
Other long-term debt							305			232
Total debt	668,734			717,902			648,178			666,448
Less: current portion of long-term debt	(125,590		)	(14,732		)	(130,664		)	(139,373		)
Long-term debt	$	543,144		$	703,170		$	517,514		$	527,075

Our credit agreement dated September 23, 2011 provides for a $299,750 term loan, a €69,414 Euro term loan and a $350,000 revolving credit facility. ~~Under specified circumstances, we have the ability to increase the term loan and/or revolving line of credit by up to~~ ~~$250,000~~ ~~in the aggregate.~~ The term loan facility matures in 20 quarterly installments with the last installment due September 23, 2016. The $350,000 revolving facility also matures on September 23, 2016 and requires no scheduled payment before that date. The book value of our term and revolving loans approximates fair value.

The credit agreement includes certain customary representations and warranties, events of default, notices of material adverse changes to our business and negative and affirmative covenants. As of ~~September 29, 2012~~March 30, 2013, we were compliant with all financial covenants specified in the credit agreement. We had $~~4,325~~5,030 outstanding under letters of credit as of ~~September 29, 2012~~March 30, 2013.

Our 350,000 of 2.25% Senior Convertible Debentures (the 2013 Notes) are due in June 2013 with interest payable semi-annually and are convertible into cash for the principal amount and shares of our common stock for the conversion premium (or, at our election, cash in lieu of some or all of such common stock), if any, based on an initial conversion rate, subject to adjustment, of 20.4337 shares of our common stock per 1,000 principal amount of notes (which represents an initial conversion price of $48.94 per share). The 2013 Notes are convertible only in the following circumstances and to the following extent:

(1) during any fiscal quarter beginning after July 1, 2006 (and only during such fiscal quarter), if the last reported sale price of our common stock for at least 20 trading days in the period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter is more than 130% of the conversion price on the last day of such preceding fiscal quarter;

(2) during the five business-day period after any five consecutive trading-day period, or the measurement period, in which the trading price per note for each day of that measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such day;

(3) upon the occurrence of specified corporate transactions, as described in the indenture for the 2013 Notes; and

(4) at the option of the holder at any time beginning on the date that is two months prior to the stated maturity date and ending on the close of business on the second trading-day immediately preceding the maturity date.

Upon conversion, we will pay cash and shares of our common stock (or, at our election, cash in lieu of some or all of such common stock), if any. If we undergo a fundamental change as described in the indenture for the 2013 Notes, holders will have the option to require us to purchase all or any portion of their notes for cash at a price equal to 100% of the principal amount of the notes to be purchased plus any accrued and unpaid interest, including any additional interest to, but excluding, the purchase date. As of March 30, 2012, no conversion triggers were met.

As of ~~September 29, 2012~~March 30, 2013, our debt included $349,995 of 2.25% Senior Convertible Debentures (2013 Notes) due June 2013. At ~~September 29, 2012~~March 30, 2013, the fair value of these outstanding 2013 Notes was approximately $~~353,915~~353,145 based on their quoted market ~~value and no conversion triggers were met.~~

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Continued)

(dollars in thousands, except per share amounts)

value. The ~~current~~long term portion of the 2013 Notes is $~~101,833~~244,995, which ~~represents~~is based upon our expected capacity on our existing credit facility available to settle the ~~amount~~2013 Notes. Upon maturity, we expect to settle ~~upon maturity through available cash and future borrowings. We expect to settle the remaining balance on~~ the 2013 Notes utilizing the expected capacity on our ~~current revolving~~existing credit facility, ~~when the 2013 Notes mature.~~our existing cash and marketable securities and other financing alternatives.

As of ~~September 29, 2012~~March 30, 2013, $~~10,556~~2,897 of debt discount related to the 2013 Notes remained and will be amortized over 3one ~~quarters.~~final quarter. Interest expense related to our convertible debt of $~~3,877~~3,830 and $3,514 for quarters ~~ended~~ending ~~September 29, 2012~~March 30, 2013 and ~~September 24, 2011~~March 31, 2012, respectively, yielded an effective interest rate of 6.93% on the liability component. In addition, $1,969 and $1,969 of contractual interest expense was recognized on our convertible debt during the quarters ended ~~September 29, 2012~~March 30, 2013 and ~~September 24, 2011~~March 31, 2012, respectively.

~~CHARLES RIVER LABORATORIES INTERNATIONAL, INC.~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Continued)~~

~~(dollars in thousands, except per share amounts)~~

Principal maturities of existing debt, which excludes unamortized discount, for the periods set forth in the table below are as follows:

Twelve Months Ending
September 2013 $ 128,757
September 2014 43,142
September 2015 58,830
September 2016 448,561
September 2017 —
Total $ 679,290



Twelve Months Ending
March 2014	$	131,534
March 2015	48,709
March 2016	59,950
March 2017	410,882
March 2018	—
Total	$	651,075

We have capital leases for equipment. These leases are capitalized using interest rates considered appropriate at the inception of the lease. Capital lease obligations amounted to $12707 and $4372 at ~~September 29, 2012~~March 30, 2013 and December ~~31, 2011~~29, 2012, respectively.

8. EQUITY

Earnings Per Share

Basic earnings per share for the three ~~and~~ ~~nine~~months ended ~~September 29, 2012~~March 30, 2013 and ~~September 24, 2011~~March 31, 2012 was computed by dividing earnings available to common shareowners for these periods by the weighted average number of common shares outstanding in the respective periods adjusted for contingently issuable shares. The weighted average number of common shares outstanding for the three ~~and~~months ended ~~nine months endedSeptember 29, 2012~~March 30, 2013 and ~~September 24, 2011~~March 31, 2012 has been adjusted to include common stock equivalents for the purpose of calculating diluted earnings per share for these periods.

Options to purchase ~~4,667,739~~2,684,236 shares and ~~4,253,703~~4,395,903 shares were outstanding ~~in each of the three months ended~~at ~~September 29, 2012~~March 30, 2013 and ~~September 24, 2011, respectively, but were not included in computing diluted earnings per share because their inclusion would have been anti-dilutive. Options to purchase~~ ~~4,590,418~~ ~~shares and~~ ~~4,245,953~~ ~~shares were outstanding in each of the~~ ~~nine months endedSeptember 29,~~March 31, 2012 ~~and~~ ~~September 24, 2011~~, respectively, but were not included in computing diluted earnings per share because their inclusion would have been anti-dilutive. Basic weighted average shares outstanding for ~~the three months ended~~ ~~September 29, 2012~~March 30, 2013 and ~~September 24, 2011~~March 31, 2012 excluded the weighted average impact of ~~1,232~~1,149,622 and ~~705,662~~930,193 shares, respectively, of non-vested ~~fixed restricted stock awards. Basic weighted average shares outstanding for the~~ ~~nine months endedSeptember 29, 2012~~ ~~and~~ ~~September 24, 2011~~ ~~excluded the weighted average impact of~~ ~~6,719~~ ~~and 705,662 shares, respectively, of non-vested fixed~~ restricted stock awards.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Continued)

(dollars in thousands, except per share amounts)

The following table illustrates the reconciliation of the numerator and denominator in the computations of the basic and diluted earnings per share:


	Three Months Ended						Nine Months Ended						Three Months Ended
	September 29, 2012			September 24, 2011			September 29, 2012			September 24, 2011			March 30, 2013			March 31, 2012
Numerator:
Income from continuing operations for purposes of calculating earnings per share	$	22,154		$	18,816		$	78,942		$	88,146		$	25,733		$	26,362
Income (loss) from discontinued businesses	(182		)	$	(18	)	$	(63	)	$	(5,695	)	(155		)	$	77
Denominator:
Weighted-average shares outstanding—Basic	47,625,806			50,084,850			48,028,602			51,671,559			47,658,995			48,254,950
Effect of dilutive securities:
2.25% senior convertible debentures	—			—			—			—			—			—
Stock options and contingently issued restricted stock	482,808			448,897			447,544			566,868			777,054			516,793
Weighted-average shares outstanding—Diluted	48,108,614			50,533,747			48,476,146			52,238,427			48,436,049			48,771,743
Basic earnings per share from continuing operations attributable to common shareowners	$	0.47		$	0.38		$	1.64		$	1.71		$	0.54		$	0.55
Basic earnings (loss) per share from discontinued operations attributable to common shareowners	$	—		$	—		$	—		$	(0.11	)
Basic earnings per share from discontinued operations attributable to common shareowners													$	—		$	—
Diluted earnings per share from continuing operations attributable to common shareowners	$	0.46		$	0.37		$	1.63		$	1.69		$	0.53		$	0.54
Diluted earnings (loss) per share from discontinued operations attributable to common shareowners	$	—		$	—		$	—		$	(0.11	)
Diluted earnings per share from discontinued operations attributable to common shareowners													$	—		$	—

Treasury Shares

For the ~~nine~~three months ended ~~September 29, 2012~~March 30, 2013 and ~~September 24, 2011~~March 31, 2012, we repurchased ~~1,222,432~~157,283 shares of common stock for $~~42,800~~6,458 and ~~2,946,468~~347,968 shares of common stock for $~~105,852~~12,500, respectively, through open market purchases made in reliance on ~~Rules 10b5-1 and 10b-18 of the Securities Exchange Act of 1934, as amended.~~Rule 10b5-1. Additionally, our ~~2000~~2007 Incentive Plan permits the netting of common stock upon vesting of restricted stock awards in order to satisfy individual tax withholding requirements. During the ~~nine~~three months ended~~September 29, 2012~~March 30, 2013 and ~~September 24, 2011~~March 31, 2012, we acquired ~~84,086~~111,515 shares for $~~3,042~~4,471 and ~~79,663~~82,375 shares for $~~2,942~~2,980, respectively, as a result of such withholdings. ~~The~~ ~~nine months endedSeptember 24, 2011~~ ~~also includes the acquisition of~~ ~~4,637,732~~ ~~shares under accelerated stock repurchase programs (ASR).~~

Share repurchases for the ~~nine~~three months ended~~September 29, 2012~~March 30, 2013 and ~~September 24, 2011~~March 31, 2012 were as follows:


	Nine Months Ended				Three Months Ended
	September 29, 2012		September 24, 2011		March 30, 2013		March 31, 2012
Number of shares of common stock repurchased	1,306,518		7,663,863		268,798		430,343
Total cost of repurchase	$	45,842	$	277,420	$	10,929	$	15,480

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Continued)

(dollars in thousands, except per share amounts)

9. INCOME TAXES

The following table provides a reconciliation of the provision for income taxes on the condensed consolidated statements of income:


	Three Months Ended				Nine Months Ended				Three Months Ended
	September 29, 2012		September 24, 2011		September 29, 2012		September 24, 2011		March 30, 2013			March 31, 2012
Income from continuing operations before income taxes	28,395		24,541		103,541		100,008		$	35,648		$	35,146
Effective tax rate	21.2	%	22.9	%	23.3	%	11.6	%	27.3		%	24.7		%
Provision (benefit) for income taxes	6,011		5,630		24,140		11,564		$	9,722		$	8,676

Our overall effective tax rate was ~~21.2%~~27.3% in the ~~third~~first quarter of ~~2012~~2013 and ~~22.9%~~24.7% in the ~~third~~first quarter of ~~2011.~~2012. The ~~change~~increase was primarily attributable to a change in French tax ~~benefit recorded~~law that was enacted during the first quarter of 2013 and limits the deductibility of interest by our French affiliates. This new tax law applies retroactively to 2012 resulting in the ~~third~~recognition of a discrete tax cost in the first quarter of ~~2012~~2013 of $~~1,226~~703 from the settlement of a Canadian tax controversy related to Scientific Research and Experimental Development (SR&ED) credits claimed in 2003 and 2004 and adjustments to the uncertain tax position related to the Canadian SR&ED credits claimed during open years. We also recognized a benefit of ~~$256~~ ~~during the third quarter of 2012 due to remeasurement of our deferred taxes for the decline in statutory tax rate in the United Kingdom.~~. The effective tax rate for the ~~third~~first quarter of ~~2011~~2013 also reflects ~~benefits of~~a $~~1,366~~525 ~~due~~tax cost related to ~~the settlement of a German tax audit and~~ ~~$486~~ ~~due to remeasurement of our deferred taxes~~nondeductible transaction costs incurred in 2012 for the ~~decline in the statutory tax rate in the United Kingdom. These benefits are partially offset by a detriment reflected in the third quarter~~acquisition of ~~2011 of~~ ~~$747~~ ~~for a provision to return adjustment in the United States primarily related to the cost of 2010 repatriation.~~

~~The effective tax rate for the nine months ended September 29, 2012 reflects an unbenefitted capital loss of~~ ~~$712~~ ~~on the sale of auction rate securities recorded~~Vital River, which closed in the first quarter of ~~2012. Additionally,~~2013, and a discrete benefit of $330 for the ~~effective~~retroactive impact of a change in US Federal tax ~~rate for~~ ~~the nine months ended September 24, 2011~~ ~~reflects an~~ ~~$11,111~~ ~~tax benefit recorded in~~law enacted during the first quarter of ~~2011 associated with a tax loss incurred with~~2013 related to the ~~disposition of the Company's Phase I clinical business and the receipt of a~~ U.S. anti deferral regime.~~$7,710~~ ~~tax exempt gain on the settlement of a life insurance policy received in the second quarter of 2011~~.

In accordance with Canadian Federal tax law, we claim ~~SR&ED~~scientific research and experimental development (SR&ED) credits on qualified research and development costs incurred by our preclinical services facility in Canada in the performance of projects for non-Canadian clients. Additionally, in accordance with the tax law of the United Kingdom, we claim enhanced deductions related to qualified research and development costs incurred by our preclinical services facility in Edinburgh, Scotland, in the performance of certain client contracts.

During the fourth quarter of 2010, we took actions to divest our Phase 1 clinical business. We recorded in discontinued operations a deferred tax asset associated with the excess of the tax outside basis over the basis for financial reporting purposes of the Phase I clinical business. As of the fourth quarter of 2010, we determined that we did not meet the more-likely-than-not realization threshold for this deferred tax asset and we recorded a valuation allowance against it as part of discontinued operations. During the first quarter of 2011, we determined that the tax loss would more-likely-than-not be benefitted as a worthless stock deduction. As such, we released the valuation allowance recorded against the tax loss on the Phase I clinical business and recognized the benefit in continuing operations.

~~During~~ ~~the third quarter of 2012~~,2013, our unrecognized tax benefits recorded ~~decreased~~increased by $~~811~~1,238 to $~~28,069~~32,234 due primarily ~~due~~ to a new uncertain tax position related to tax incentives claimed by Vital River in prior years. Additionally, the ~~settlement~~unrecognized tax benefits increased during the first quarter of ~~Canadian SR&ED controversies for years 2003 and 2004 partially offset by increases~~2013 due to ongoing evaluation of uncertain tax positions in the current ~~and prior periods~~period offset by a reduction due to a settlement of a Quebec audit and foreign exchange movement. The amount of unrecognized income tax benefits that would impact the effective tax rate favorably ~~decreased~~increased by $~~1,260~~1,411 to $~~21,776~~26,007,. The increase was due primarily to a new uncertain tax position that arose in the first quarter of 2013 relating to the acquisition to Vital River as well as an increase due to ongoing evaluation of uncertain tax positions in the ~~Canadian SR&ED controversy settlement.~~current period offset by foreign exchange movement. The amount of accrued interest on unrecognized tax benefits increased by $~~194~~347 to $~~1,739~~2,312 in the ~~third~~first quarter of ~~2012~~ ~~primarily due to the revaluation of current and prior period exposures.~~2013.

We conduct business in a number of tax jurisdictions. As a result, we are subject to tax audits in jurisdictions including, but not limited to, the United States, the United Kingdom, Japan, France, Germany and Canada. With few exceptions, we are no longer subject to U.S. and international income tax examinations for years before 2005.

We and certain of our subsidiaries are currently under audit by the ~~Canadian~~Minister of Revenue ~~Authority (CRA)~~Quebec provincial tax authority (MRQ) and various state tax authorities. ~~With few~~We do not believe that resolution of these controversies will have a material impact on our financial position or results of operations.

We are currently under audit by the Canadian Revenue Authority (CRA) for the years 2006 through 2009. In the fourth quarter of 2012, we received a draft reassessment from the CRA related to the transfer pricing in our Preclinical services operations in Montreal. The CRA proposes to disallow certain deductions related to headquarter service charges for the years 2006 through 2009. We intend to file an objection with the CRA upon receipt of the Notice of Reassessment and apply to the Internal Revenue Service (IRS) and the CRA for relief pursuant to the competent authority procedure provided in the tax treaty between the U.S. and Canada. We believe that the controversy will likely be ultimately settled via the competent authority process. In the fourth quarter of 2012, we established a reserve for this uncertain tax position of $2,408 related to years 2006 through 2012 to reduce the tax benefit recognized for these deductions in Canada to the level that we believe will likely be realized upon the ultimate resolution of this controversy. Additionally, in the fourth quarter of 2012, we recognized a tax asset of $2,981, which is included in Other Assets, that represents the correlative relief that we believe will more likely than not be received in the U.S.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Continued)

(dollars in thousands, except per share amounts)

~~exceptions, we are no longer subject to U.S. and international income tax examinations for years before 2005.~~

~~During~~via the ~~third quarter of 2012, we reached a settlement with the Canadian Department of Justice with respect to our appeal~~competent authority process. The actual amounts of the ~~CRA's reassessments of our 2003~~liability for Canadian taxes and ~~2004 SR&ED claims to~~ the ~~Tax Court of Canada. As agreed to~~asset for the correlative relief in the ~~settlement,~~U.S. could be different based upon the ~~CRA issued final reassessments in~~agreement reached between the ~~third quarter of 2012~~IRS and ~~we filed a Notice of Discontinuance with the Tax Court of Canada concluding the controversy. In the third quarter, we recorded a benefit due to the settlement of~~ ~~$586, of which~~ ~~$248~~ ~~is recorded in pretax profit and~~ ~~$338~~ ~~is recorded in tax expense. Our SR&ED claims in 2005 and forward remain open to audit. The settlement agreement for 2003 and 2004 does not apply to these open years.~~ CRA.

We believe ~~that~~ we have appropriately provided for ~~these claims as well as~~ all uncertain tax positions.

In accordance with our policy, the undistributed earnings of our non-U.S. subsidiaries remain indefinitely reinvested as of the end of the ~~third~~first quarter of ~~2012~~2013 as they are required to fund needs outside the U.S. and cannot be repatriated in a manner that is substantially tax free.

~~The~~For the three months ended March 30, 2013, income tax expense ~~(benefit)~~of $904 related to items of other comprehensive income ~~are as follows:~~

Three Months Ended Nine Months Ended
September 29, 2012 September 24, 2011 September 29, 2012 September 24, 2011
Tax expense (benefit) related to foreign currency translation adjustment (60 ) 456
(98 ) 835
Tax expense related to change in unrecognized pension gains, losses and prior service costs 216
116
799
276
Income tax expense related to items of other comprehensive income $ 156
$ 572
$ 701
$ 1,111

included an expense of $662 related to foreign currency translation adjustments and an expense of $242 related to the change in unrecognized pension gains, losses and prior service costs. For the three months ended March 31, 2012, income tax expense of $261 related to items of other comprehensive income included a benefit of $89 related to foreign currency translation adjustments and an expense of $350 related to the change in unrecognized pension gains, losses and prior service costs.

10. EMPLOYEE BENEFITS

The following table provides the components of net periodic benefit cost for our defined benefit ~~plans for the three month period ended:~~plans:

Pension Benefits
Supplemental
Retirement Benefits
September 29, 2012 September 24, 2011 September 29, 2012 September 24, 2011
Service cost $ 922
$ 758
$ 160
$ 159
Interest cost 2,824
3,016
223
300
Expected return on plan assets (3,459 ) (3,407 ) —
—
Amortization of prior service cost (credit) (256 ) (155 ) 165
125
Amortization of net loss (gain) 586
239
65
53
Net periodic benefit cost 617
451
613
637
Company contributions $ 2,096
$ 1,100
$ —
$ —

~~CHARLES RIVER LABORATORIES INTERNATIONAL, INC.~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Continued)~~

~~(dollars in thousands, except per share amounts)~~

~~The following table provides thecomponents of net periodic benefit cost for our defined benefit plans for the~~ ~~nine~~ ~~month period ended:~~


	Pension Benefits						Supplemental Retirement Benefits				Pension Benefits						Supplemental Retirement Benefits
	September 29, 2012			September 24, 2011			September 29, 2012		September 24, 2011		March 30, 2013			March 31, 2012			March 30, 2013		March 31, 2012
Service cost	2,880			2,279			480		477		$	847		$	979		$	161	$	160
Interest cost	8,445			9,056			669		901		2,810			2,811			177		223
Expected return on plan assets	(10,319		)	(10,213		)	—		—		(3,656		)	(3,430		)	—		—
Amortization of prior service cost (credit)	(566		)	(466		)	495		374		(150		)	(151		)	165		165
Amortization of net loss (gain)	1,756			693			195		158		690			582			63		65
Net periodic benefit cost	2,196			1,349			1,839		1,910		$	541		$	791		$	566	$	613
Company contributions	$	10,104		$	7,119		$	—	$	—

During ~~2012~~2013, we expect to contribute $~~13,868~~9,686 to our ~~defined benefit~~pension plans.

11. STOCK PLANS AND ~~STOCK-BASED~~STOCK BASED COMPENSATION

The estimated fair value of our stock-based awards, less expected forfeitures, is amortized over the awards' vesting period on a straight-line basis. The following table presents stock-based compensation included in our consolidated statement of income:


	Three Months Ended						Nine Months Ended
	September 29, 2012			September 24, 2011			September 29, 2012			September 24, 2011			March 30, 2013			March 31, 2012
Stock-based compensation expense included in:
Cost of sales	$	1,271		$	1,626		$	3,995		$	5,003		$	1,369		$	1,448
Selling and administration	3,970			3,945			11,833			11,916			4,535			3,818
Stock-based compensation, before income taxes	5,241			5,571			15,828			16,919			5,904			5,266
Provision for income taxes	(1,847		)	(1,991		)	(5,615		)	(6,050		)	(2,043		)	(1,884		)
Stock-based compensation, net of tax	$	3,394		$	3,580		$	10,213		$	10,869		$	3,861		$	3,382

The fair value of stock-based awards granted during the first ~~nine~~three months of ~~2012~~2013 and ~~2011~~2012 was estimated on the grant date using the Black-Scholes option-pricing model with the following weighted-average assumptions:

September 29, 2012 September 24, 2011
Expected life (in years) 4.5
4.2
Expected volatility 34.9 % 33.4 %
Risk-free interest rate 0.84 % 2.22 %
Expected dividend yield 0 % 0 %
Weighted-average grant date fair value $ 10.94
$ 11.35

2019

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Continued)

(dollars in thousands, except per share amounts)



	March 30, 2013			March 31, 2012
Expected life (in years)	4.2 years			4.5 years
Expected volatility	32.7		%	35.0		%
Risk-free interest rate	0.81		%	0.84		%
Expected dividend yield	0		%	0		%
Weighted-average grant date fair value	$	11.15		$	11.02

Stock Options

The following table summarizes stock option activities under our plans:


	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)	Aggregate Intrinsic Value		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)	Aggregate Intrinsic Value
Options outstanding as of December 31, 2011	6,081,263		$	38.25
Options outstanding as of December 29, 2012								5,860,403		$	39.11
Options granted	590,675		$	36.09				564,629		$	40.40
Options exercised	(436,611	)	$	28.18				(800,097	)	$	31.58
Options canceled	(145,514	)	$	39.09				(13,021	)	$	44.03
Options outstanding as of September 29, 2012	6,089,813		$	38.74	3.39 years	$	23,680
Options exercisable as of September 29, 2012	4,088,672		$	39.80	2.53 years	$	14,286
Options outstanding as of March 30, 2013								5,611,914		$	40.31	3.40 years	$	32,445
Options exercisable as of March 30, 2013								3,944,595		$	41.31	2.45 years	$	21,884

As of ~~September 29, 2012~~March 30, 2013, the unrecognized compensation cost related to ~~2,000,796~~1,667,319 unvested stock options expected to vest was $~~14,723~~16,721. This unrecognized compensation will be recognized over an estimated weighted-average amortization period of 2832 months.

The total intrinsic value of options exercised during the three months ~~ended~~ending ~~September 29, 2012~~March 30, 2013 and ~~September 24, 2011~~March 31, 2012 was $~~1,461~~8,891 and $~~1,204~~1,131, respectively, with intrinsic value defined as the difference between the market price on the date of exercise and the grant date price. The total ~~intrinsic value of options exercised during the~~ ~~nine months endedSeptember 29, 2012~~ ~~and~~ ~~September 24, 2011~~ ~~was~~ ~~$2,769~~ ~~and~~ ~~$7,914, respectively. The total~~ amount of cash received from the exercise of options during the three months ending ~~nine months endedSeptember 29, 2012~~March 30, 2013 and ~~September 24, 2011~~March 31, 2012 was $~~12,304~~25,148 and $~~20,574~~2,715, respectively. The actual tax benefit realized for the tax deductions from option exercises ~~during~~totaled $3,207 for the three months ending ~~nine months endedSeptember 29, 2012~~ ~~was~~ ~~$821~~March 30, 2013. A charge of $101,794 was recorded in capital in excess of par value in the first ~~nine~~ ~~months of 2012~~quarter for the excess of deferred tax assets over the actual tax benefits at option exercise. We settle stock option exercises with newly issued common shares.

Restricted Stock

Stock compensation expense associated with restricted common stock is charged for the market value on the date of grant, less estimated forfeitures, and is amortized over the awards' vesting period on a straight-line basis.

The following table summarizes the restricted stock activity for the three months ending ~~the nine months ended September 29, 2012~~March 30, 2013:

Restricted Stock Weighted
Average
Grant Date
Fair Value
Outstanding as of December 31, 2011 703,011
$ 35.70
Granted 541,820
36.10
Vested (286,344 ) 35.96
Canceled (16,614 ) 35.48
Outstanding as of September 29, 2012 941,873
$ 35.85

~~As of~~ ~~September 29, 2012, the unrecognized compensation cost related to shares of unvested restricted stock expected to vest was~~ ~~$24,221. This unrecognized compensation will be recognized over an estimated weighted-average amortization period of~~ ~~33 months. The total fair value of restricted stock grants that vested during the three and~~ ~~nine months endedSeptember 29, 2012~~ ~~was~~ ~~$91~~ ~~and~~ ~~$10,297, respectively. The total fair value of restricted stock grants that vested during the three and~~ ~~nine months endedSeptember 24, 2011~~ ~~was~~ ~~$122~~ ~~and~~ ~~$10,985, respectively. The actual tax benefit realized for the tax deductions from restricted stock grants that vested during~~ ~~the nine months ended September 29, 2012~~ ~~was~~ ~~$3,690~~.



	Restricted Stock		Weighted Average Grant Date Fair Value
Outstanding as of December 29, 2012	934,505		$	35.83
Granted	546,316		40.40
Vested	(329,098	)	40.08
Canceled	(2,101	)	41.04
Outstanding as of March 30, 2013	1,149,622		$	36.78

2120

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Continued)

(dollars in thousands, except per share amounts)

As of March 30, 2013, the unrecognized compensation cost related to shares of unvested restricted stock expected to vest was $39,827. This unrecognized compensation will be recognized over an estimated weighted-average amortization period of 36 months. The total fair value of restricted stock grants that vested during the quarters ending March 30, 2013 and March 31, 2012 was $13,190 and $9,392, respectively. The actual tax benefit realized for the tax deductions from restricted stock grants that vested totaled $4,622 for the three months ended March 30, 2013.

Performance Based Stock Award Program

On February 22, 2013, we granted 167,694 Performance Share Units (PSUs) to certain executive officers. The PSUs will be paid out in our common stock based upon the results of two metrics: performance based on our earnings per share with certain defined adjustments and our relative stock price market performance based on a 3-year relative Total Shareholder Return calculation. Accordingly, the actual total number of our shares into which the granted PSUs will convert can range from no shares to a maximum of 335,388 shares. The PSUs will become fully vested in December 2015 and will be paid out in the form of our common stock in the first quarter of 2016. Compensation expense associated with the PSUs of $233 has been recorded during the three months ended March 30, 2013.

12. COMMITMENTS AND CONTINGENCIES

Various lawsuits, claims and proceedings of a nature considered normal to our business are pending against us. In the opinion of management, the outcome of such proceedings and litigation currently pending will not materially affect our consolidated financial statements.

13. BUSINESS SEGMENT INFORMATION

We report two business ~~segments:~~segments, Research Models and Services (RMS) and Preclinical Services (PCS). Our RMS segment includes sales of research models, genetically engineered models and services (GEMS), insourcing solutions (IS), research animal diagnostic services (RADS), discovery research services (DRS), Endotoxin and Microbial Detection (EMD) products and services, ~~(formerly~~ ~~in vitro~~), and avian vaccine products and services. Our PCS segment includes services required to take a drug through the development process, which ~~include discovery research services (DRS),~~includes DRS, safety assessment and biopharmaceutical services.

The following table presents sales and other financial information by business segment.

Three Months Ended Nine Months Ended
September 29, 2012 September 24, 2011 September 29, 2012 September 24, 2011
Research Models and Services
Net sales $ 166,484
$ 171,471
$ 523,247
$ 523,005
Gross margin 65,902
70,514
224,364
222,660
Operating income 43,389
48,534
158,398
155,967
Depreciation and amortization 9,670
9,327
27,697
27,914
Capital expenditures 7,423
5,789
27,892
14,202
Preclinical Services
Net sales $ 112,202
$ 106,108
$ 326,143
$ 328,680
Gross margin 27,358
22,202
76,693
79,014
Operating income 10,975
3,663
25,958
20,844
Depreciation and amortization 10,880
11,840
32,920
36,334
Capital expenditures 2,819
2,433
5,903
7,470

~~A reconciliation of segment operating income to consolidated operating income is as follows:~~

Three Months Ended Nine Months Ended
September 29, 2012 September 24, 2011 September 29, 2012 September 24, 2011
Total segment operating income $ 54,364
$ 52,197
$ 184,356
$ 176,811
Unallocated corporate overhead (16,682 ) (15,103 ) (53,660 ) (44,152 )
Consolidated operating income $ 37,682
$ 37,094
$ 130,696
$ 132,659



	Three Months Ended
	March 30, 2013		March 31, 2012
Research Models and Services
Net sales	$	182,489	$	183,152
Gross margin	80,435		82,196
Operating income	55,303		59,467
Depreciation and amortization	9,873		8,942
Capital expenditures	4,010		12,900
Preclinical Services
Net sales	$	108,749	$	102,829
Gross margin	23,776		22,016
Operating income	8,060		4,174
Depreciation and amortization	10,137		11,060
Capital expenditures	2,418		1,211

2221

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Continued)

(dollars in thousands, except per share amounts)

A reconciliation of segment operating income to consolidated operating income is as follows:



	Three Months Ended
	March 30, 2013			March 31, 2012
Total segment operating income	$	63,363		$	63,641
Unallocated corporate overhead	(20,600		)	(19,901		)
Consolidated operating income	$	42,763		$	43,740

Net sales for each significant service area are as follows:


	Three Months Ended				Nine Months Ended				Three Months Ended
	September 29, 2012		September 24, 2011		September 29, 2012		September 24, 2011		March 30, 2013		March 31, 2012
Research models	$	79,552	$	86,386	$	260,692	$	269,976	$	103,123	$	104,932
Research model services	53,586		54,539		163,892		161,936		52,154		56,071
Other products	33,346		30,546		98,663		91,093
Research Models and Services	166,484		171,471		523,247		523,005
Preclinical Services	112,202		106,108		326,143		328,680
EMD									27,212		22,149
Total research models									182,489		183,152
Total preclinical services									108,749		102,829
Total sales	$	278,686	$	277,579	$	849,390	$	851,685	$	291,238	$	285,981

A summary of unallocated corporate overhead consists of the following:


	Three Months Ended						Nine Months Ended						Three Months Ended
	September 29, 2012			September 24, 2011			September 29, 2012			September 24, 2011			March 30, 2013		March 31, 2012
Stock-based compensation expense	$	2,827		$	2,825		$	8,512		$	8,339		$	3,197	$	2,785
U.S. retirement plans	1,276			501			3,662			2,613			1,300		1,372
Audit, tax and related expense	842			855			2,133			2,115			1,235		654
Salary and bonus	4,813			3,187			14,602			12,522			4,755		4,923
Global IT	3,285			3,089			9,501			9,623			2,586		2,850
Employee health, long-term disability and fringe benefit expense	(2,248		)	(2,307		)	(1,395		)	7			2,228		1,993
Consulting and professional services	1,061			2,628			3,581			6,160			688		1,742
Depreciation expense	1,554			1,569			4,693			4,743			1,570		1,569
Life insurance death benefit gain	—			—			—			(7,710		)
Other general unallocated corporate expenses	3,272			2,756			8,371			5,740			3,041		2,013
Total unallocated corporate overhead costs	$	16,682		$	15,103		$	53,660		$	44,152		$	20,600	$	19,901

Other general unallocated corporate expenses consist of various departmental costs including those associated with departments such as senior executives, corporate accounting, legal, tax, human resources, treasury and investor relations.

14. DISCONTINUED OPERATIONS

On March 28, 2011, we disposed of our Phase I clinical business for a nominal amount. As part of the disposition we remained the guarantor of the Phase I facility lease. During the second quarter of 2011, we recognized the value of the guarantee net of the buyer's related indemnity as a liability of $2,994, which we are accreting ratably over the remaining term of the lease. The facility lease runs through January 2021 with remaining lease payments totaling $~~13,632~~12,630 as of ~~September 29, 2012~~March 30, 2013. The consolidated financial statements have been reclassified to segregate, as discontinued operations, the assets and liabilities, operating results and cash flows, of the businesses being discontinued for all periods presented.

2322

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Continued)

(dollars in thousands, except per share amounts)

During the period ended December 29, 2012, we concluded that the decreasing financial viability of the lessee increased the probability that we will be required to make future lease payments as guarantor. As a result, we recorded an additional contingent loss for the guarantee, reflecting our estimate of the total future lease payments less sublease income. Under the terms of the lease, if we are required to honor the guarantee due to default by the lessee, we may obtain control of the leased property.

On April 4, 2013 the buyer of our Phase I clinical business filed for Chapter 11 bankruptcy. As a result, we revised our contingent loss for the guarantee, reflecting our revised estimate of the total future lease payments less sublease income. The total carrying amount of the liability for our obligation under the guarantee is $9,829 as of March 30, 2013 and is reflected on the consolidated balance sheet a liability of discontinued operations.

The consolidated financial statements classify, as discontinued operations, the assets and liabilities, operating results and cash flows, of businesses that are discontinued for all periods presented. Operating results from discontinued operations are as follows:


	Three Months Ended						Nine Months Ended						Three Months Ended
	September 29, 2012			September 24, 2011			September 29, 2012			September 24, 2011			March 30, 2013			March 31, 2012
Net sales	$	—		$	—		$	—		$	2,122		$	—		$	—
Income (loss) from operations of discontinued businesses, before income taxes	49			24			221			(8,129		)	(220		)	104
Provision (benefit) for income taxes	231			42			284			(2,434		)	(65		)	27
Income (loss) from operations of discontinued businesses, net of taxes	$	(182	)	$	(18	)	$	(63	)	$	(5,695	)	$	(155	)	$	77

Assets and liabilities of discontinued operations at ~~September 29, 2012~~March 30, 2013 and December ~~31, 2011~~29, 2012 consisted of the following:


	September 29, 2012		December 31, 2011		March 30, 2013		December 29, 2012
Current assets	$	109	$	107	$	705	$	495
Long-term assets	903		986		3,177		3,328
Total assets	$	1,012	$	1,093	$	3,882	$	3,823
Current liabilities	$	1,092	$	1,165	$	2,633	$	1,802
Long-term liabilities	2,311		2,522		8,126		8,795
Total liabilities	$	3,403	$	3,687	$	10,759	$	10,597

Current ~~assets~~ and ~~non-current~~long-term assets include ~~a short-term and long-term~~ deferred tax ~~asset related to lease guarantee.~~assets. Current and long-term liabilities consist primarily of ~~the carrying value of the~~a lease ~~guarantee and accrued expenses.~~

~~15. BUSINESS ACQUISITIONS~~

In ~~August 2012, we acquired Accugenix Inc. (Accugenix), for~~ ~~$18,434~~ in cash, subject to adjustments. Accugenix is a global provider of cGMP-compliant contract microbial identification testing. The acquisition strengthens our EMD portfolio of products and services by providing state-of-the-art microbial detection services for the biotechnology, pharmaceutical, and medical device manufacturing industries. Accugenix is based in the U.S. and is included in our RMS reportable business segment.

~~The preliminary purchase price allocation, net of~~ ~~$1,532~~ ~~of cash acquired is as follows:~~

Current assets (excluding cash) $ 2,189
Property, plant and equipment 549
Current liabilities (1,084 )
Long term liabilities (3,572 )
Goodwill and other finite-lived intangible assets 18,820
Total purchase price allocation $ 16,902

guarantee.

2423

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Continued)

(dollars in thousands, except per share amounts)

~~The preliminary breakout of goodwill and finite-lived intangible assets acquired are as follows:~~

Weighted average amortization life (in years)
Client relationships $ 1,600
13
Proprietary database 3,900
11
Standard operating procedures 2,500
4
Trademarks and trade names 300
12
Goodwill $ 10,520

Total goodwill and other intangible assets $ 18,820

The finite-lived intangibles are largely attributed to a proprietary database of thousands of species of organisms and the methods and technology to provide accurate, timely and cost-effective microbial identification services. The goodwill resulting from the transaction is primarily attributed to the potential for growth of the Company's global EMD products and services business through the increased competitive advantage and market penetration provided by the services offered by Accugenix. The goodwill is not deductible for tax purposes.

~~16. SUBSEQUENT EVENTS~~15. BUSINESS ACQUISITIONS

In October 2012, we entered into an agreement to acquire a 75% ~~majority~~ ownership interest of Vital River, a commercial provider of research models and related services in China, for approximately $~~27,000~~26,890 in cash, subject to certain closing adjustments. The acquisition ~~is expected to close~~closed in ~~the first quarter of~~January 2013 ~~subject to customary closing conditions, including regulatory approvals.~~. Vital River's financial results are included in our RMS reportable business segment.

The preliminary purchase price allocation, net of $2,671 of cash acquired, is as follows:



Current assets (excluding cash)	$	2,994
Property, plant and equipment	10,404
Other long-term assets	2,242
Definite-lived intangible assets	15,623
Goodwill	19,687
Current liabilities	(11,792		)
Long term liabilities	(5,976		)
Redeemable noncontrolling interest	(8,963		)
Total purchase price allocation	$	24,219

The preliminary breakout of definite-lived intangible assets acquired are as follows:



			Weighted average amortization life (in years)
Client relationships	$	14,292	11.7 years
Reacquired rights	1,171		1.3 years
Other intangible assets	160		2.8 years
Total definite-lived intangible assets	$	15,623

The definite-lived intangibles are largely attributed to the expected cash flows related to customer relationships existing at the acquisition closing date. In addition, the Company reacquired a right previously granted to the entity related to a royalty agreement for the distribution of products in China. The value assigned to the reacquired right will be amortized over the remaining life of the existing royalty agreement. The goodwill resulting from the transaction is primarily attributed to the potential growth of the business in China. The goodwill is not deductible for tax purposes.

Concurrent with the acquisition, the Company entered into a joint venture agreement with the noncontrolling interest holders that provide the Company with the right to purchase the remaining 25% of the entity for cash at its then appraised value beginning in January 2016. Additionally, the noncontrolling interest holders were granted the right to require the Company to purchase the remaining 25% of the entity at its then appraised value in January 2016 for cash. These rights are accelerated in certain events. As the noncontrolling interest holders can require the Company to purchase for cash the remaining 25% interest, we classify the carrying amount of the noncontrolling interest above the equity section and below liabilities on the consolidated balance sheet and we adjust the carrying amount to fair value each quarter end. Adjustments to fair value are recorded through additional paid-in capital.

2524

Item 2.7. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following Management's Discussion and Analysis will help you understand our financial condition and results of operations. The Management's Discussion and Analysis is a supplement to, and should be read in conjunction with, our consolidated financial statements and the accompanying notes to the consolidated financial statements.

Overview

We are a leading global provider of solutions that advance the drug discovery and development process, including research models and associated services and outsourced preclinical services. We provide our products and services to global pharmaceutical companies and biotechnology companies, as well as government agencies, leading hospitals and academic institutions throughout the world in order to bring drugs to market faster and more efficiently. We have built upon our core competency of in vivo biology, including laboratory animal medicine and science (research model technologies) to develop a diverse portfolio of preclinical services - both GLP (Good Laboratory Practice) and non-GLP - which address drug discovery and development. Utilizing our broad portfolio of products and services enables our clients to create a more flexible drug development model which reduces their costs, enhances their productivity and effectiveness, and increase speed to market. We have been in business for over 65 years and currently operate approximately 6465 facilities in 15 countries worldwide.

Large pharmaceutical and biotechnology companies have been undergoing significant change ~~for the last few~~in recent years as they endeavor to improve the productivity of their drug development pipelines, and at the same time, streamline their infrastructures in order to improve efficiency and reduce operating costs. Our clients' efforts have had an unfavorable impact on our operations as a result ~~of:~~of our clients' measured research and development ~~spending by major pharmaceutical and biotechnology companies;~~spending; delays in ~~customer~~ decisions and commitments; tight cost constraints and the resultant pricing pressure, particularly in view of excess capacity in the contract research industry; and a focus on late-stage clinical testing as ~~customers~~our clients accelerate their efforts to bring drugs to market in the face of expiration of patents on branded ~~drugs;~~drugs. There were other trends which also affected us unfavorably: biotechnology companies experienced a period of decreased funding, which has only recently improved as a result of investments by global pharmaceutical companies and a moderate improvement in the public markets for ~~biopharmaceutical~~these companies; ~~and the impact of~~uncertainty surrounding healthcare reform ~~initiatives. In addition,~~initiatives; and consolidation in the pharmaceutical and biotechnology ~~industry has affected demand for our products and services.~~industry. All of these ongoing factors continue to contribute to demand uncertainty and are expected to impact future sales.

Over the last ~~year,~~two years, demand for our ~~market for goods~~products and services appears to have continued to stabilize. As part of our clients' efforts to improve pipeline productivity, pharmaceutical and biotechnology companies are emphasizing efficacy testing in order to eliminate ~~therapies~~molecules from the pipeline earlier in the drug development process. This trend is visible in increasing demand for our non-GLP in vivo pharmacology and drug metabolism and pharmacokinetics (DMPK) services. We continue to anticipate that our clients will reduce their internal capacity through closure of underutilized facilities and increase their use of these outsourced services in the future, because utilizing outsourced services enables them to create a flexible drug development model which improves operating efficiency and reduces costs.

As our clients increase focus on strategic outsourcing, our scientific expertise, operating efficiency, ~~informational~~information technology platforms and ~~our~~client data portals, and ability to meet each client's individual needs strongly positions us to compete for business. We continue to ~~formalize the expansion of our~~build momentum by winning new or renewing existing strategic relationships with our clients. ~~During the third quarter, AstraZeneca~~We continue to be selected ~~us as its preferred~~for these strategic ~~partner for outsourced regulated safety assessment and development DMPK (drug metabolism and pharmacokinetics) for a three-year period. We won this partnership~~relationships in a highly competitive marketplace because of the characteristics noted above, as well as our broad portfolio of products and services ~~scientific expertise~~which span the early-stage drug development continuum, and our ability to develop a customized in vivo biology program to support our client's drug development efforts. Price ~~was~~continues to be a factor in ~~the bid~~our bids but we believe our scientific expertise ~~was~~remains a key criterion. ~~This is~~Our ongoing discussions concerning additional strategic relationships continue as our ~~second significant strategic client agreement with a global pharmaceutical company. Last year,~~clients focus on the logistics of outsourcing. Additionally, we ~~signed a large, five-year agreement with a leading global pharmaceutical company to become the client's primary~~ ~~in vivo~~ ~~biology partner. We~~ continue to ~~make progress and build momentum on~~expand our ~~strategic~~ relationships with our ~~clients. Additionally,~~mid-tier and academic clients by focusing our sales and marketing efforts in ~~the fourth quarter we were awarded a partnership with BIOCOM in which we were named the premier supplier of research models for this Southern California purchasing consortium.~~ order to achieve market share gains.

We believe that the long-term drivers for our business as a whole will primarily emerge from our clients' continued demand for research models and services and both GLP and non-GLP in vivo biology services, which are essential to the drug development process. However, presently it is challenging to predict the timing associated with these drivers.

We continue to focus on our four key initiatives designed to allow us to drive profitable growth and to maximize value for shareholders, and thus better position ourselves to operate successfully in the current and future business environment. These four initiatives are:

~~Improving~~ improving the consolidated operating ~~margin.~~ ~~We continue to aggressively manage our cost structure and drive operating efficiencies, which are expected to generate improvement in our operating margins. We have already~~

~~implemented significant actions to reduce costs during the last two years to manage challenging industry-wide preclinical market conditions. During the~~ ~~first nine months of 2012~~, we continued to selectively adjust our cost structure by headcount reductions and other cost initiatives including the consolidation of certain RMS production facilities commencing during the third quarter of 2012.

~~Improving~~margin, improving free cash flow ~~generation.~~ ~~We believe we have adequate capacity to support revenue growth in both business segments without significant additional investment for expansion. Capital expenditures were~~ ~~$33.8 million~~ ~~in the~~ ~~first nine months of 2012~~ ~~and we expect capital expenditures to be approximately $50.0 million for this year.~~

~~Disciplined~~generation, disciplined investment in growth ~~businesses.~~ ~~We continue~~businesses and returning value to ~~maintain a~~shareholders. Our continued actions, which include aggressively driving operating efficiencies, disciplined focus on deployment of capital, investing in those areas of our existing business ~~which will generate~~with the greatest ~~sales~~potential for growth and profitability, such as Genetically Engineered Models and Services (GEMS), Research Animal Diagnostic Services (RADS), Discovery Research Services (DRS) and Endotoxin and Microbial Detection (EMD, formerly In Vitro) products and services. During the third quarter we acquired Accugenix, Inc., a global provider of cGMP-compliant contract microbial identification testing, which strengthens our EMD portfolio of products and services by providing clients with state-of-the-art microbial detection services for manufacturing in the biopharmaceutical, medical device, nutraceutical and consumer care industries. In addition, during the third quarter we opened a new biomedical diagnostic testing facility in Wilmington, Massachusetts. The state-of-the-art, 60,000-square-foot R&D services facility expands our diagnostic capabilities for research model health monitoring, clinical chemistry, hematology, biomarker assay development and immunoassay services.

~~Returning value to shareholders.~~ ~~We are~~ repurchasing ~~our~~ stock with the intent to drive immediate shareholder value and earnings per

share ~~accretion. During~~accretion, are significant actions toward the achievement of our four key initiatives. The acquisition of Vital River completed in the first ~~nine months of 2012 and 2011, we repurchased~~ ~~1.3 million~~ ~~and~~ ~~7.7 million~~ ~~shares, respectively. Our weighted average shares outstanding for~~ ~~the third~~ quarter of ~~2012~~ ~~have decreased to~~ ~~48.1 million~~ ~~shares from~~ ~~50.5 million~~ ~~shares for~~ ~~the third quarter~~2013 is an example of ~~2011~~.

our focus on investing in growth businesses.

Total net sales during the ~~third~~first quarter of ~~2012~~2013 were $~~278.7~~291.2 million, an increase of ~~0.4%~~1.8% over the same period last year. The sales increase was due primarily to ~~Preclinical Services (PCS),~~increased sales for the PCS segment partially offset by ~~the~~lower RMS sales. The effect of foreign currency translation ~~which~~ had a negative impact on sales of ~~3.2%~~1.0%. On a segment basis, sales increased in the Preclinical Services (PCS) segment due mainly to increased demand for safety assessment services, but declined in the Research Models and Services (RMS) segment due primarily to foreign currency translation. Our gross margin ~~increased~~decreased to ~~33.5%~~35.8% of net sales for the ~~third~~first quarter of ~~2012~~2013 compared to ~~33.4%~~36.4% of net sales for the ~~third~~first quarter of ~~2011~~2012., due primarily to lower sales of research models. Our operating income was $~~37.7~~42.8 million for the ~~third~~first quarter of ~~2012~~2013 compared to operating income of $~~37.1~~43.7 million for the ~~third~~first quarter of ~~2011~~2012, an ~~increase~~decrease of ~~1.6%~~2.1% due ~~primarily~~ to ~~impact of increased PCS sales. Operating~~the decline in Research Model and Services segment. The operating margin was ~~13.5%~~14.7% for the ~~third~~first quarter of ~~2012~~2013, compared to~~13.4%~~15.3% for the ~~third~~first quarter of ~~2011~~2012.

Our net income attributable to common shareholders was $~~22.0~~25.6 million for the three months ended ~~September 29, 2012~~March 30, 2013 compared to $~~18.8~~26.4 million for the three months ended ~~September 24, 2011~~March 31, 2012. Diluted earnings per share for the ~~third~~first quarter of ~~2012~~2013 ~~was~~were $~~0.46~~0.53 compared to diluted earnings per share of $~~0.37~~0.54 for the ~~third~~first quarter of ~~2011~~.

~~Total net sales during~~ ~~the nine months ended September 29,~~ 2012 ~~were~~ ~~$849.4 million, a decrease of~~ ~~0.3%~~ ~~over the same period last year. The sales decrease was due primarily to the effect of foreign currency translation, which had a negative impact on sales of 2.4%. Our gross margin was flat at~~ ~~35.4%~~ ~~of net sales for~~ ~~the nine months ended September 29, 2012~~ ~~compared to~~ ~~the nine months ended September 24, 2011. Our operating income was~~ ~~$130.7 million~~ ~~for~~ ~~the nine months ended September 29, 2012~~ ~~compared to operating income of~~ ~~$132.7 million~~ ~~for~~ ~~the nine months ended September 24, 2011, a decrease of~~ ~~1.5%~~ ~~due to a prior year insurance gain of $7.7 million. Operating margin was~~ ~~15.4%~~ ~~for~~ ~~the nine months ended September 29, 2012, compared to~~ ~~15.6%~~ ~~for~~ ~~the nine months ended September 24, 2011~~.

~~Our net income attributable to common shareholders was~~ ~~$78.9 million~~ ~~for~~ ~~the nine months ended September 29, 2012~~ ~~compared to~~ ~~$82.5 million~~ ~~for~~ ~~the nine months ended September 24, 2011. Diluted earnings per share for~~ ~~the nine months ended September 29, 2012~~ ~~was~~ ~~$1.63~~ ~~compared to diluted earnings per share of~~ ~~$1.58~~ ~~for~~ ~~the nine months ended September 24, 2011~~.

We report two segments: Research Models and Services (RMS) and Preclinical Services (PCS), which reflects the manner in which our operating units are managed.

Our RMS segment, which represented ~~59.7%~~62.7% of net sales in the ~~third~~first quarter of ~~2012~~2013, includes three categories: ~~production of research models,~~Research Models, Research Model Services, and ~~Other Products.~~Endotoxin and Microbial Detection (EMD). Research Models includes production of small and large research models as well as avian products. Research Model Services include four business units: Genetically Engineered Models and Services (GEMS), Research Animal ~~Diagnostics~~Diagnostic Services (RADS), Discovery Research

Services (DRS), and Insourcing Solutions (IS). ~~Other Products includes our Endotoxin and Microbial Detection (EMD) and Avian Vaccine Services businesses.~~ Net sales for the RMS segment decreased ~~2.9%~~0.4% compared to the ~~third~~first quarter of ~~2011~~2012, primarily driven by lower sales of Research Models and Research Model Services, partially offset by higher sales of EMD and the acquisition of Vital River. The effect of foreign currency translation ~~which~~ had a negative impact on sales of ~~4.1%~~1.4%. The gross margin ~~percentage was~~ ~~39.6%~~ ~~compared~~decreased to ~~41.1%~~44.1% infrom 44.9% primarily due to the ~~prior year.~~impact of lower sales on our fixed costs partially, offset by our cost savings. The operating margin ~~percentage~~ decreased to ~~26.1%~~30.3% from ~~28.3%~~32.5% ~~last year.~~.

Our PCS segment, which represented ~~40.3%~~37.3% of net sales in the ~~third~~first quarter of ~~2012~~2013, includes services required to take a drug through the development process including discovery support, safety assessment and biopharmaceutical services. Sales for this segment increased ~~5.7%~~5.8% from the ~~third~~first quarter of ~~2011~~2012 ~~due mainly~~, as a result of increased sales to ~~increased demand for safety assessment services, partially offset by the impact~~both large biopharmaceutical and mid-tier clients, primarily as a result of ~~foreign~~continued market share gains. Foreign currency translation ~~which~~ reduced the sales growth rate by ~~1.8%. We experienced an increase~~0.2% in the first quarter of 2013. The PCS gross margin increased to ~~24.4%~~21.9% from ~~20.9%~~21.4% in the ~~third~~first quarter of ~~2011~~2012~~, primarily attributable to the impact of the increased sales.~~. The operating margin for the ~~third~~first quarter of ~~2012~~2013 was ~~9.8%~~7.4%, compared to ~~3.5%~~4.1% in the ~~third~~first quarter of ~~2011~~2012., due mainly to higher sales of both regulated safety assessment and non-GLP discovery services, as well as a modest improvement in profitability for biopharmaceutical services compared to last year's challenging start.

Three Months Ended ~~September 29, 2012~~March 30, 2013 Compared to the Three Months Ended ~~September 24, 2011~~March 31, 2012

Net Sales. Net sales for the three months ended ~~September 29, 2012~~March 30, 2013 were $~~278.7~~291.2 million, an increase of $~~1.1~~5.2 million, or ~~0.4%~~1.8%, from $~~277.6~~286.0 million for the three months ended ~~September 24, 2011~~March 31, 2012, due primarily to increased sales for PCS partially offset by ~~unfavorable~~lower RMS sales. The effect of foreign currency translation had a negative impact on sales of ~~3.2%~~1.0%.

Research Models and Services. For the three months ended ~~September 29, 2012~~March 30, 2013, net sales for our RMS segment were $~~166.5~~182.5 million, a decrease of $~~5.0~~0.7 million, or ~~2.9%~~0.4%, from $~~171.5~~183.2 million for the three months ended ~~September 24, 2011~~March 31, 2012, due primarily to lower sales of Research Models and Research Model Services partially offset by higher sales of EMD and the acquisition of Vital River. The effect of unfavorable foreign currency translation ~~which~~ decreased sales by ~~4.1% partially offset by Other Product sales, which include our Avian and Endotoxin and Microbial Detection (EMD) businesses.~~1.4%.

Preclinical Services. For the three months ended ~~September 29, 2012~~March 30, 2013, net sales for our PCS segment were $~~112.2~~108.7 million, an increase of $~~6.1~~5.9 million, or ~~5.7%~~5.8%, from $~~106.1~~102.8 million for the three months ended ~~September 24, 2011~~March 31, 2012. The sales increase was ~~driven by~~a result of increased ~~demand for safety assessment services, partially offset by unfavorable foreign~~sales to both large biopharmaceutical and mid-tier clients, primarily as a result of continued market share gains. Foreign currency translation ~~of 1.8%~~reduced the sales growth rate by 0.2%.

Cost of Products Sold and Services Provided. Cost of products sold and services provided during the ~~third~~first quarter of ~~2012~~2013 was $~~185.4~~187.0 million, an increase of $~~0.5~~5.2 million, or ~~0.3%~~2.9%, from $~~184.9~~181.8 million during the ~~third~~first quarter of ~~2011~~2012. Cost of products sold and services provided during the three months ended ~~September 29, 2012~~March 30, 2013 was ~~66.5%~~64.2% of net sales, compared to ~~66.6%~~63.6% during the three months ended ~~September 24, 2011~~March 31, 2012.

Research Models and Services. Cost of products sold and services provided for RMS during the ~~third~~first quarter of ~~2012~~2013 was $~~100.6~~102.1 million, ~~a decrease~~an increase of $~~0.4~~1.1 million, or ~~0.4%~~1.1%, compared to $101.0 million in ~~2011~~2012. Cost of products sold and

services provided for the three months ended ~~September 29, 2012~~March 30, 2013 ~~was~~increased to ~~60.4%~~55.9% of net sales compared to ~~58.9%~~55.1% of net sales for ~~2011~~2012. The increase in cost as a percentage of sales was primarily due to the impact of lower sales on our fixed costs partially offset by our cost savings.

Preclinical Services. Cost of services provided for the PCS segment induring the ~~third~~first quarter of ~~2012~~2013 was $~~84.8~~85.0 million, an increase of $~~0.9~~4.2 million, compared to $~~83.9~~80.8 million in ~~the third quarter of~~ ~~2011~~2012. Cost of services provided as a percentage of net sales was ~~75.6%~~78.1% during the three months ended ~~September 29, 2012~~March 30, 2013, compared to ~~79.1%~~78.6% for the three months ended ~~September 24, 2011~~March 31, 2012. The decrease in cost of services provided as a percentage of net sales was primarily ~~attributable~~due to ~~the impact~~higher sales of ~~the increased capacity utilization, cost savings actions~~both regulated safety assessment and ~~the impact of higher sales.~~non-GLP discovery services, as well as a modest improvement in profitability for biopharmaceutical services compared to last year's challenging start.

Selling, General and Administrative Expenses. Selling, general and administrative expenses for the three months ended ~~September 29, 2012~~March 30, 2013 were $~~51.0~~57.2 million, an increase of $~~0.7~~1.2 million, or ~~1.4%~~2.1%, from $~~50.3~~56.0 million for the three months ended ~~September 24, 2011~~March 31, 2012. Selling, general and administrative expenses infor the ~~third~~first quarter of ~~2012~~2013 were ~~18.3%~~19.6% of net sales compared to ~~18.1%~~19.6% for the ~~third~~first quarter of ~~2011~~2012.

Research Models and Services. Selling, general and administrative expenses for RMS for the ~~third~~first quarter of ~~2012~~2013 were $~~20.9~~23.1 million, an increase of $~~0.5~~1.9 million, or ~~2.5%~~9.0%, compared to $~~20.4~~21.2 million in ~~2011~~2012. Selling, general and administrative expenses increased as a percentage of sales to ~~12.6%~~12.7% for the three months ended ~~September 29, 2012~~March 30, 2013 from ~~11.9%~~11.6% for the three months ended ~~September 24, 2011~~March 31, 2012 due ~~mainly~~ to ~~impairment charges related~~increases to support higher growth areas and the ~~consolidation~~impact of ~~facilities in Europe, partially offset by cost savings actions.~~the acquisitions of Accugenix and Vital River.

Preclinical Services. Selling, general and administrative expenses for the PCS segment for the ~~third~~first quarter of ~~2012~~2013 were $13.5 million, ana decrease of $1.3 million, or ~~9.3%~~9.4%, compared to $14.8 million during ~~the third quarter of~~ ~~2011~~2012. Selling, general and administrative expenses for the three months ended ~~September 29, 2012~~March 30, 2013 decreased to ~~12.0%~~12.4% of net sales, compared to ~~14.0%~~14.4% of net sales for the three months ended ~~September 24, 2011~~March 31, 2012, due mainly to ~~cost savings actions and~~lower severance expense ~~control.~~

~~Unallocated Corporate Overhead.~~ Unallocated corporate overhead, which consists of various costs primarily associated with activities centered at our corporate headquarters, such as compensation (including stock-based compensation), information systems, compliance and facilities expenses associated with our corporate, administration and professional services functions, was ~~$16.7 million~~ ~~during~~ ~~the three months ended September 29, 2012, compared to~~ ~~$15.1 million~~ ~~during~~ ~~the three months ended September 24, 2011. The increase was primarily due to increased compensation and fringe related costs.~~

~~Amortization of Other Intangibles.~~ ~~Amortization of other intangibles for~~ ~~the three months ended September 29, 2012~~ ~~was~~ ~~$4.5 million, a decrease of~~ ~~$0.8, from~~ ~~$5.3 million~~ ~~for~~ ~~the three months ended September 24, 2011. Amortization expense decreased as a percentage of sales to~~ ~~1.6%~~ ~~for~~ ~~the three months ended September 29, 2012, from~~ ~~1.9%~~ ~~for~~ ~~the three months ended September 24, 2011~~.

~~Research Models and Services.~~ In ~~the third quarter of 2012, amortization of other intangibles for our RMS segment was~~ ~~$1.6 million~~ ~~which is flat compared to~~ ~~the third quarter of 2011~~.

~~Preclinical Services.~~ ~~For~~ ~~the three months ended September 29, 2012, amortization of other intangibles for our PCS segment was~~ ~~$2.9 million, a decrease of~~ ~~$0.8~~ ~~million from~~ ~~$3.7 million~~ ~~for~~ ~~the three months ended September 24, 2011~~.

~~Operating Income.~~ ~~Operating income for~~ ~~the three months ended September 29, 2012~~ ~~was~~ ~~$37.7 million, an increase of~~ ~~$0.6~~ ~~million compared to operating income of~~ ~~$37.1 million~~ ~~for~~ ~~the three months ended September 24, 2011. Operating income as a percentage of net sales for~~ ~~the three months ended September 29, 2012~~ ~~was~~ ~~13.5%~~ ~~compared to~~ ~~13.4%~~ ~~for~~ ~~the three months ended September 24, 2011~~.

~~Research Models and Services.~~ ~~For~~ ~~the three months ended September 29, 2012, operating income for our RMS segment was~~ ~~$43.4 million, a decrease of~~ ~~$5.1~~ ~~million, or~~ ~~10.6%, from~~ ~~$48.5 million~~ ~~for~~ ~~the three months ended September 24, 2011. Operating income as a percentage of net sales for~~ ~~the three months ended September 29, 2012~~ ~~was~~ ~~26.1%, compared to~~ ~~28.3%~~ ~~for~~ ~~the three months ended September 24, 2011. The decrease in operating income as a percentage of net sales was primarily due to the impact of our fixed costs with lower sales.~~

~~Preclinical Services.~~ ~~For~~ ~~the three months ended September 29, 2012, operating income for our PCS segment was~~ ~~$11.0 million, an increase of~~ ~~$7.3~~ ~~million compared to~~ ~~$3.7 million~~ ~~for~~ ~~the three months ended September 24, 2011. Operating income as a percentage of net sales increased to~~ ~~9.8%~~ ~~compared to~~ ~~3.5%~~ ~~of net sales in~~ ~~the three months ended September 24, 2011. The increase in operating income as a percentage of net sales was primarily due to increased sales and the lower amortization expense.~~

~~Unallocated Corporate Overhead.~~ ~~Unallocated corporate overhead was~~ ~~$16.7 million~~ ~~during~~ ~~the three months ended September 29, 2012, compared to~~ ~~$15.1 million~~ ~~during~~ ~~the three months ended September 24, 2011. The increase was primarily due to increased compensation and fringe related costs.~~

~~Interest Expense.~~ ~~Interest expense for~~ ~~the third quarter of 2012~~ ~~was~~ ~~$8.5 million, compared to~~ ~~$11.9 million~~ ~~for~~ ~~the third quarter of 2011. The decrease was due mainly to decreased debt balances and lower interest rates.~~

~~Interest Income.~~ ~~Interest income for~~ ~~the third quarter of 2012~~ ~~was~~ ~~$0.1 million, compared to~~ ~~$0.1 million~~ ~~for~~ ~~the third quarter of 2011~~ ~~due to lower cash balances and lower interest rates on invested funds.~~

~~Income Taxes.~~ ~~Income tax expense for~~ ~~the three months ended September 29, 2012~~ ~~was~~ ~~$6.0 million, an increase of~~ ~~$0.4~~ ~~million compared to income tax expense of~~ ~~$5.6 million~~ ~~for~~ ~~the three months ended September 24, 2011. Our effective tax rate was~~ ~~21.2%~~ ~~for~~ ~~the three months ended September 29, 2012~~ ~~compared to~~ ~~22.9%~~ ~~for~~ ~~the three months ended September 24, 2011. The decrease of 1.7%~~ in the ~~effective tax rate for~~ ~~the three months ended September 29, 2012~~ was primarily attributable to a tax detriment of $0.7 million recorded in the three months ended September 24, 2011 for a provision to return adjustment in the United States primarily due to the cost of 2010 repatriation. Additionally, the effective tax rate for the three months ended September 24, 2011 reflects tax benefits from the German audit settlement of $1.4 million and a decline in the statutory tax rate in the United Kingdom of $0.5 million. The effective tax rate for the three months ended September 29, 2012 reflects tax benefits from the settlement of the Canadian tax controversy of $1.2 million and a decline in the statutory tax rate in the United Kingdom of $0.3 million.

~~Net Income Attributable to Common Shareowners.~~ ~~Net income attributable to common shareowners for~~ ~~the three months ended September 29, 2012~~ ~~was~~ ~~$22.0 million~~ ~~compared to~~ ~~$18.8 million~~ ~~for~~ ~~the three months ended September 24, 2011~~.

~~Nine Months EndedSeptember 29, 2012~~ ~~Compared to the~~ ~~Nine Months EndedSeptember 24, 2011~~

~~Net Sales.~~ ~~Net sales for~~ ~~the nine months ended September 29, 2012~~ ~~were~~ ~~$849.4 million, a decrease of~~ ~~$2.3~~ ~~million, or~~ ~~0.3%, from~~ ~~$851.7 million~~ ~~for~~ ~~the nine months ended September 24, 2011, due primarily to impact of unfavorable foreign currency translation of 2.4% .~~

~~Research Models and Services.~~ ~~For~~ ~~the nine months ended September 29, 2012, net sales for our RMS segment were~~ ~~$523.2 million, an increase of~~ ~~$0.2~~ ~~million, or~~ ~~0.0%, from~~ ~~$523.0 million~~ ~~for~~ ~~the nine months ended September 24, 2011~~, due primarily to higher Other Product sales, which include our Avian and EMD businesses, as well as Research Model Services. The effect of unfavorable foreign currency translation decreased sales by 2.9%.

~~Preclinical Services.~~ ~~For~~ ~~the nine months ended September 29, 2012, net sales for our PCS segment were~~ ~~$326.1 million, a decrease of~~ ~~$2.6~~ ~~million, or~~ ~~0.8%, from~~ ~~$328.7 million~~ ~~for~~ ~~the nine months ended September 24, 2011~~. The sales decrease was driven by unfavorable sales mix with a greater proportion of non-GLP discovery services as well as lower sales of biopharmaceutical services combined with unfavorable foreign currency translation of 1.6%.

~~Cost of Products Sold and Services Provided.~~ ~~Cost of products sold and services provided during~~ ~~the nine months ended September 29, 2012~~ ~~was~~ ~~$548.3 million, a decrease of~~ ~~$1.7~~ ~~million, or~~ ~~0.3%, from~~ ~~$550.0 million~~ ~~during~~ ~~the nine months ended September 24, 2011. Cost of products sold and services provided during~~ ~~the nine months ended September 29, 2012~~ ~~was flat at~~ ~~64.6%~~ ~~of net sales, compared to~~ ~~64.6%~~ ~~during~~ ~~the nine months ended September 24, 2011~~.

~~Research Models and Services.~~ ~~Cost of products sold and services provided for RMS during~~ ~~the nine months ended September 29, 2012~~ ~~was~~ ~~$298.9 million, a decrease of~~ ~~$1.4~~ ~~million, or~~ ~~0.5%, compared to~~ ~~$300.3 million~~ in ~~2011. Cost of products sold and services provided for~~ ~~the nine months ended September 29, 2012~~ ~~decreased to~~ ~~57.1%~~ ~~of net sales compared to~~ ~~57.4%~~ ~~of net sales for~~ ~~2011. The decrease in cost as a percentage of sales was primarily due to the impact of sales and our cost savings actions.~~

~~Preclinical Services.~~ ~~Cost of services provided for the PCS segment during~~ ~~the nine months ended September 29, 2012~~ ~~was~~ ~~$249.5 million, a decrease of~~ ~~$0.2~~ ~~million, compared to~~ ~~$249.7 million~~ ~~during~~ ~~the nine months ended September 24, 2011. Cost of services provided as a percentage of net sales was~~ ~~76.5%~~ ~~during~~ ~~the nine months ended September 29, 2012, compared to~~ ~~76.0%~~ ~~for~~ ~~the nine months ended September 24, 2011~~. The increase in cost of services provided as a percentage of net sales was primarily due to the impact of lower sales on our fixed cost base and the transfer of client protocols under an expanded preferred provider agreement with a global pharmaceutical client.

~~Selling, General and Administrative Expenses.~~ ~~Selling, general and administrative expenses for~~ ~~the nine months ended September 29, 2012~~ ~~were~~ ~~$156.9 million, an increase of~~ ~~$4.3~~ ~~million, or~~ ~~2.8%, from~~ ~~$152.6 million~~ ~~for~~ ~~the nine months ended September 24, 2011. Selling, general and administrative expenses~~ ~~the nine months ended September 29, 2012~~ ~~were~~ ~~18.5%~~ ~~of net sales compared to~~ ~~17.9%~~ ~~for~~ ~~the nine months ended September 24, 2011~~.

~~Research Models and Services.~~ ~~Selling, general and administrative expenses for RMS for~~ ~~the nine months ended September 29, 2012~~ ~~were~~ ~~$61.4 million, a decrease of~~ ~~0.3~~ ~~million, or~~ ~~0.4%, compared to~~ ~~$61.7 million~~ in ~~the nine months ended September 24, 2011. Selling, general and administrative expenses decreased as a percentage of sales to~~ ~~11.7%~~ ~~for~~ ~~the nine months ended September 29, 2012~~ ~~from~~ ~~11.8%~~ ~~for~~ ~~the nine months ended September 24, 2011. The decrease in selling, general and administrative expenses as a percent of sales was primarily due to cost savings actions and an insurance settlement related to our Japan operations.~~

~~Preclinical Services.~~ ~~Selling, general and administrative expenses for the PCS segment for~~ ~~the nine months ended September 29, 2012~~ ~~were~~ ~~$41.8 million, a decrease of~~ ~~$4.9~~ ~~million, or~~ ~~10.4%, compared to~~ ~~$46.7 million~~ ~~during~~ ~~the nine months ended September 24, 2011. Selling, general and administrative expenses for~~ ~~the nine months ended September 29, 2012~~ ~~decreased to~~ ~~12.8%~~ ~~of net sales, compared to~~ ~~14.2%~~ ~~of net sales for~~ ~~the nine months ended September 24, 2011, due mainly to cost savings actions and expense control.~~current period.

Unallocated Corporate Overhead. Unallocated corporate overhead, which consists of various costs primarily associated with activities centered at our corporate headquarters, such as compensation (including stock-based compensation), information systems, compliance and facilities expenses associated with our corporate, administration and professional services functions, was $~~53.7~~20.6 million during the ~~nine~~three months ended ~~September 29, 2012~~March 30, 2013, compared to $~~44.2~~19.9 million during the ~~nine~~three months ended ~~September 24, 2011~~March 31, 2012. The increase in the first quarter of 2013 was primarily due to ~~the one-time effect of a prior year insurance gain of $7.7 million.~~cost increases across several expense categories.

Amortization of Other Intangibles. Amortization of other intangibles for the ~~nine~~three months ended ~~September 29, 2012~~March 30, 2013 was $~~13.4~~4.2 million, a decrease of $~~3.1~~0.3 ~~million,~~, from $~~16.5~~4.5 million for the ~~nine~~three months ended ~~September 24, 2011~~March 31, 2012. Amortization expense decreased as a percentage of sales to 1.5% for the three months ended March 30, 2013, from 1.6% for the ~~nine~~three months ended ~~September 29,~~March 31, 2012~~, from~~ ~~1.9%~~ ~~for~~ ~~the nine months ended September 24, 2011~~.

Research Models and Services. In the ~~nine months ended September 29, 2012~~first quarter of 2013, amortization of other intangibles for our RMS segment was $~~4.5~~2.0 million, ~~a decrease~~an increase of $0.5 million from $~~5.0~~1.5 million in the ~~nine months ended September 24, 2011~~first quarter of 2012. due mainly to the acquisition of Vital River.

Preclinical Services. For the ~~nine~~three months ended ~~September 29, 2012~~March 30, 2013, amortization of other intangibles for our PCS segment was $~~8.9~~2.3 million, a decrease of $~~2.6~~0.7 million from $~~11.5~~3.0 million for the ~~nine~~three months ended ~~September 24, 2011~~March 31, 2012.

Operating Income. Operating income for the ~~nine~~three months ended ~~September 29, 2012~~March 30, 2013 was $~~130.7~~42.8 million, a decrease of $~~2.0~~0.9 million compared to operating income of $~~132.7~~43.7 million for the ~~nine~~three months ended ~~September 24, 2011~~March 31, 2012. Operating income as a percentage of net sales for the ~~nine~~three months ended ~~September 29, 2012~~March 30, 2013 was ~~15.4%~~14.7% compared to ~~15.6%~~15.3% for the ~~nine~~three months ended ~~September 24, 2011~~March 31, 2012.

Research Models and Services. For the ~~nine~~three months ended ~~September 29, 2012~~March 30, 2013, operating income for our RMS segment was $~~158.4~~55.3 million, ~~an increase~~a decrease of $~~2.4~~4.2 million, or ~~1.6%~~7.0%, from $~~156.0~~59.5 million in ~~the nine months ended September 24, 2011~~2012. Operating income as a percentage of net sales for the ~~nine~~three months ended ~~September 29, 2012~~March 30, 2013 was 30.3%, compared to ~~29.8%~~32.5% for the ~~nine~~three months ended ~~September 24, 2011~~March 31, 2012. The decrease in operating income as a percentage of net sales was primarily due to the impact impact of lower sales on our fixed costs partially offset by our cost savings.

Preclinical Services. For the three months ended March 30, 2013, operating income for our PCS segment was $8.1 million, an increase of $3.9 million compared to $4.2 million for the three months ended March 31, 2012. Operating income as

a percentage of net sales increased to 7.4% compared to 4.1% of net sales in 2012. The increase in operating income as a percentage of net sales was primarily due to higher sales and ~~cost-savings actions.~~

~~Preclinical Services.~~ ~~For~~ the ~~nine months ended September 29, 2012, operating income~~increased profitability for our ~~PCS segment was~~ ~~$26.0 million, an increase of~~ ~~$5.2~~ ~~million compared to~~ ~~$20.8 million~~ ~~for~~ ~~the nine months ended September 24, 2011. Operating income as a percentage of net sales increased to~~ ~~8.0%~~ ~~compared to~~ ~~6.3%~~ ~~of net sales in~~ ~~the nine months ended September 24, 2011. The increase in operating income as a percentage of net sales was primarily due to cost-savings actions~~biopharmaceutical services.

Unallocated Corporate Overhead. Unallocated corporate overhead was $~~53.7~~20.6 million during the ~~nine~~three months ended ~~September 29, 2012~~March 30, 2013, compared to $~~44.2~~19.9 million during the ~~nine~~three months ended ~~September 24, 2011~~March 31, 2012. The increase in the first quarter of 2013 was primarily due to ~~prior year insurance gain of $7.7 million.~~increased stock based compensation and fringe related costs.

Interest Expense. Interest expense for the ~~nine months ended September 29, 2012~~first quarter of 2013 was $~~25.0~~8.3 million, compared to $~~32.6~~8.4 million in the ~~nine months ended September 24, 2011~~first quarter of 2012. The decrease was due mainly to decreased debt balances and lower interest rates.

Interest Income. Interest income for the ~~nine months ended September 29, 2012~~first quarter of 2013 was $~~0.5~~0.1 million, compared to $~~1.1~~0.2 million for the ~~nine months ended September 24, 2011~~first quarter of 2012 due mainly to lower ~~cash balances and lower~~ interest ~~rates on invested funds.~~rates.

Income Taxes. Income tax expense for the ~~nine~~three months ended ~~September 29, 2012~~March 30, 2013 was $~~24.1~~9.7 million, an increase of ~~$12.5~~$1.0 million compared to ~~income tax expense of~~ $~~11.6~~8.7 million for the ~~nine~~three months ended ~~September 24, 2011~~March 31, 2012. Our effective tax rate was ~~23.3%~~27.3% for the ~~nine months ended September 29, 2012~~first quarter of 2013 compared to ~~11.6%~~24.7% for the ~~nine months ended September 24, 2011~~.first quarter of 2012. The increase was primarily attributable to a change in French tax law that was enacted during the first quarter of 2013 and limited the deductibility of interest by our French affiliates. This new tax law applied retroactively to 2012 resulting in the ~~effective~~recognition of a discrete tax ~~rate for~~ ~~the nine months ended September 29, 2012~~ ~~was primarily due to an $11.1 million tax benefit recorded~~cost in the first quarter of ~~2011 associated with a tax loss incurred from the disposition~~2013 of ~~our Phase I clinical business and the receipt of a $7.7 million tax exempt gain on the settlement of a life insurance policy recorded in the second quarter of 2011. Additionally, the~~$0.7 million. The effective tax rate infor the first ~~nine months~~quarter of 2013 also reflected a $0.5 million tax cost related to nondeductible transaction costs incurred in 2012 ~~includes an unbenefitted capital loss~~for the acquisition of ~~$0.7 million on the sale of our auction rate securities recorded~~Vital River, which closed in the first quarter of ~~2012.~~2013, and a discrete benefit of $0.3 million for the retroactive impact of a change in US Federal tax law enacted during the first quarter of 2013 related to the U.S. anti-deferral regime.

Net Income Attributable to Common Shareowners. Net income attributable to common shareowners for the ~~nine~~three months ended ~~September 29, 2012~~March 30, 2013 was $~~78.9~~25.6 million compared to $~~82.5~~26.4 million for the ~~nine~~three months ended ~~September 24, 2011~~March 31, 2012.

Liquidity and Capital Resources

The following discussion analyzes liquidity and capital resources by operating, investing and financing activities as presented in our consolidated statements of cash flows.

Our principal sources of liquidity have been our cash flow from operations, and proceeds from our ~~marketable securities~~long term debt and our revolving line of credit arrangements.

Our credit agreement dated September 23, 2011 provides for a $299.8 million term loan, a €69.4 million Euro term loan and a $350.0 million revolving credit facility. The term loan facility matures in 20 quarterly installments with the last installment due September 23, 2016. The $~~350~~350.0 million revolving facility also matures on September 23, 2016 and requires no scheduled payment before that date. The book value of our term and revolving loans approximates fair value.

The credit agreement includes certain customary representations and warranties, events of default, notices of material adverse changes to our business and negative and affirmative covenants. As of ~~September 29, 2012~~March 30, 2013, we were compliant with all financial covenants specified in the credit agreement. We had $~~4.3~~5.0 million outstanding under letters of credit as of ~~September 29, 2012~~March 30, 2013.

Our debt also includes $350.0 million of 2.25% Senior Convertible Debentures (2013 Notes) due June 2013. At ~~September 29, 2012~~March 30, 2013, the fair value of our outstanding 2013 Notes was approximately $~~353.9~~353.1 million based on their quoted market value and no conversion triggers were met. Upon maturity, we will settle the principal balance of the 2013 Notes in cash and any additional amount due to the conversion feature in cash or shares. WeUpon maturity, we intend to ~~utilize~~settle the ~~existing capacity of~~2013 Notes utilizing our ~~credit agreement, our existing~~ cash and marketable securities, ~~as well as evaluate~~the existing capacity on our credit facility, which includes possible increases to the term loan and revolving line of credit and/or other financing alternatives ~~to meet the cash requirement at maturity in June 2013. We classified~~ ~~$237.6 million~~ of our 2013 Notes as long term debt, which represents the amount we expect to settle by utilizing the existing capacity expected to be available on our current revolving credit facility when the 2013 Notes mature.

For the ~~nine~~three months ended~~September 29, 2012~~March 30, 2013, we repurchased ~~1,306,518~~157.3 thousand shares of common stock for $~~45.8~~6.5 million ~~million primarily~~ through open market purchases made in reliance on Rule ~~10b5-1 and 10b-18 of the Securities Exchange Act of 1934, as amended.~~10b-18. The timing and amount of any future repurchases will depend on market conditions and corporate considerations.

As of ~~September 29, 2012~~March 30, 2013, we had $~~6.4~~6.8 million in time deposits classified as marketable ~~securities. During the~~ ~~nine months endedSeptember 29, 2012, we sold our auction rate~~ securities ~~for~~ ~~$11.3 million~~ ~~in cash and recorded a realized loss of~~ ~~$0.7 million, which is included in other income (expense). The~~ ~~September 29, 2012~~ ~~balance of marketable securities was comprised of~~ ~~$6.4 million~~ held by non-U.S. subsidiaries.

Cash and cash equivalents totaled $~~83.2~~100.4 million at ~~September 29, 2012~~March 30, 2013, compared to ~~$68.9~~$109.7 million at December ~~31, 2011. At~~ ~~September~~ 29, ~~2012, the~~ ~~$83.2 million~~ of2012. The decline in cash and cash equivalents was ~~comprised~~primarily due to the repurchase of shares, capital expenditures and prepayment of debt. At March 30, 2013, the $~~7.3~~100.4 million ~~held in the United States and~~ ~~$75.9 million~~ ~~held by non-U.S. subsidiaries. At December 31, 2011, the $68.9 million~~ was comprised of ~~$0.4~~$10.5 million held in the United States and ~~$68.5~~$89.9 million held by non-U.S. subsidiaries. At December 29, 2012, the $109.7 million was comprised of $10.7 million held in the United States and $99.0 million held by non-U.S. subsidiaries. We are a net borrower and closely manage our cash to keep balances low. We were able to maintain liquidity by having the ability to borrow on our revolving line of credit.

Net cash provided by operating activities for the quarters ending ~~nine months endedSeptember 29, 2012~~March 30, 2013 and ~~September 24, 2011~~March 31, 2012 was $~~143.7~~30.0 million and $~~134.9~~25.3 million, respectively. The increase in cash provided by operations was primarily due to ~~income taxes. The tax benefit related~~stable accrued liabilities in the quarter ending March 30, 2013 compared to the ~~disposition of our Phase I clinical business, which increased net income in 2011, will be realized in cash in the future.~~quarter ending March 31, 2012. Our days sales outstanding (DSO) ~~increased to 52~~remained flat at 51 days as of ~~September~~March 30, 2013 compared to December 29, 2012, and increased compared to 48 days as of ~~December~~March 31, ~~2011 and 50 days as of~~ ~~September 24, 2011~~2012. Our DSO includes deferred revenue as an offset to accounts receivable in the calculation. Our net cash provided by operating activities will be impacted by future timing of client payments for products and services as evidenced in our DSO. A one-day increase or decrease in our DSO represents a change of approximately $3.1 million of cash provided by operating activities. Our allowance for doubtful accounts was ~~$3.9~~$4.5 million as of ~~September~~March 30, 2013 compared to $4.3 million as of December 29, 2012~~, compared to $4.0 million as of December 31, 2011.~~.

Net cash used in investing activities for the quarters ending ~~nine months endedSeptember 29, 2012~~March 30, 2013 and ~~September 24, 2011~~March 31, 2012 was $~~35.2~~28.8 million and $~~12.0~~3.3 million, respectively. The acquisition of Vital River completed in the first quarter of 2013. Our capital expenditures during the ~~nine months endedSeptember 29, 2012~~first quarter of 2013 were ~~$33.8~~$6.4 million,, of which ~~$27.9~~$4.0 million was related to RMS and ~~$5.9~~$2.4 million to PCS. For ~~2012,~~2013, we project capital expenditures to be approximately $50.0 million. We anticipate that future capital expenditures will be funded by operating activities, marketable securities and existing credit facilities. For the quarters ending ~~nine months endedSeptember 29, 2012~~March 30, 2013 and ~~September 24, 2011~~,March 31, 2012, we sold ~~$23.5~~$5.6 million and ~~$27.8~~$14.6 million of marketable securities, respectively. ~~During the third quarter of 2012 we paid~~ ~~$16.9 million~~, net of cash acquired, related to the acquisition of Accugenix. In addition, we entered into an agreement to acquire a 75% majority ownership interest of Vital River for approximately $27 million in cash. The acquisition is expected to close in the first quarter of 2013, subject to customary closing conditions, including regulatory approvals.

Net cash used in financing activities for the quarters ending ~~nine months endedSeptember 29, 2012~~March 30, 2013 and ~~September 24, 2011~~March 31, 2012 was $~~93.0~~6.5 million and $~~215.8~~30.6 million, respectively. For the quarters ending March 30, 2013 and March 31, 2012, proceeds from exercises of employee stock options were $25.1 million and $2.7 million. Proceeds from long-term debt were $~~53.1~~32.8 million and $~~235.8~~28.0 million for the quarters ending ~~nine months endedSeptember 29, 2012~~March 30, 2013 and ~~September 24, 2011~~,March 31, 2012, respectively. Payments on long-term debt and revolving credit agreements were $~~112.7~~54.9 million and $~~214.3~~46.6 million for the quarters ending ~~nine months endedSeptember 29, 2012~~March 30, 2013 and ~~September 24, 2011~~,March 31, 2012, respectively. For the quarters ending ~~nine months endedSeptember 29, 2012~~March 30, 2013 and ~~September 24, 2011~~,March 31, 2012, we paid $~~45.8~~11.2 million and $~~255.6~~15.2 million, respectively, for the purchase of treasury stock acquired through open market ~~purchases and the accelerated share repurchase program in 2011.~~purchases.

Off-Balance Sheet Arrangements

The conversion features of our 2013 Notes are equity-linked derivatives. As such, we recognize these instruments as off-balance sheet arrangements. Because the conversion features associated with these notes are indexed to our common stock and classified in stockholders' equity, these instruments are not accounted for as derivatives.

Recent Accounting Pronouncements

In ~~July 2012, the~~February 2013, The FASB issued an accounting standard update ~~that amended the rules~~ related to ~~testing indefinite-lived intangible assets.~~Comprehensive Income: Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. The ~~amendment is intended~~revised standard requires companies to ~~reduce~~present information about reclassification adjustments from accumulated other comprehensive income in their annual financial statements in a single note or on the ~~cost and complexity~~face of the ~~annual impairment test of these intangible assets. The~~financial statements. This amendment iswas effective for ~~impairment tests performed for fiscal years beginning after September 15, 2012. The amendment is not expected to have a material impact~~us on ~~our financial statements.~~December 30, 2012 and was applied prospectively.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Certain of our financial instruments are subject to market risks, including interest rate risk and foreign currency exchange rates. We generally do not use financial instruments for trading or other speculative purposes.

Interest Rate Risk

We entered into our amended credit agreement on September 23, 2011. Our primary interest rate exposure results from changes in LIBOR or the base rates which are used to determine the applicable interest rates under our term loans and revolving credit facility in the credit agreement.

Our potential additional interest expense over one year that would result from a hypothetical, instantaneous and unfavorable change of 100 basis points in the interest rate would be approximately ~~$6.5~~$6.2 million on a pre-tax basis. The book value of our debt approximates fair value.

We issued $350.0 million of the 2013 Notes in a private placement in the second quarter of 2006. The 2013 Notes bear an interest rate of 2.25%. The fair market value of the outstanding notes was approximately $~~353.9~~353.1 million on ~~September 29, 2012~~March 30, 2013.

Foreign Currency Exchange Rate Risk

We operate on a global basis and have exposure to some foreign currency exchange rate fluctuations for our earnings and cash flows. This risk is mitigated by the fact that various foreign operations are principally conducted in their respective local currencies. A portion of the revenue from our foreign operations is denominated in U.S. dollars, with the costs accounted for in their local currencies. Additionally, we have exposure on certain intercompany loans. We attempt to minimize this exposure by using certain financial instruments, for purposes other than trading, in accordance with our overall risk management and our hedge policy. In accordance with our hedge policy, we designate such transactions as hedges.

During the first ~~nine months~~quarter of ~~2012~~,2013, we utilized foreign exchange contracts, principally to hedge the impact of currency fluctuations on client transactions and certain balance sheet items, including intercompany loans. ~~The~~No foreign currency ~~contract outstanding as of~~ ~~September 29, 2012~~ ~~is a non-designated hedge, and is marked to market with changes in fair value recorded to other income (expense).~~contracts were open at quarter end.

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

Based on their evaluation, required by paragraph (b) of Rules 13a-15 or 15d-15, promulgated by the Securities Exchange Act of 1934, as amended (Exchange Act), the Company's principal executive officer and principal financial officer have concluded that because of the material weakness existing in our internal controls over financial reporting as of December 29, 2012 the Company's disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act are not effective, at a reasonable assurance level ~~as of~~ ~~September 29, 2012~~ to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and ~~forms.~~forms as of March 30, 2013. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by ~~an issuer~~the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the ~~issuer's~~Company's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurances of achieving the desired control objectives, and management necessarily was required to apply its judgment in designing and evaluating the controls and procedures.

A material weakness in internal control over financial reporting is a deficiency, or a combination of deficiencies, in internal controls over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis by the Company's internal controls.

As of December 29, 2012 management determined that the Company did not maintain effective controls over information technology business processes and financial reporting. Specifically, the Company identified deficiencies with respect to design and operation of controls over segregation of duties, restricted access, changes to vendor and customer master data, transaction level and financial close controls which aggregated to a material weakness in internal control over financial reporting.

We determined that this deficiency constitutes a "material weakness" in our internal control over financial reporting.

Based on the performance of additional procedures by management, designed to ensure the reliability of our financial reporting, including the remediation efforts outline in Item 4 (b) we believe the consolidated financial statement included in this report as of and for the periods ended March 30, 2013 are fairly stated in all material respects.

We continually are in the process of further reviewing and documenting our disclosure controls and procedures, and our internal control over financial reporting, and accordingly may from time to time make changes aimed at enhancing their effectiveness and to ensure that our systems evolve with our business.


(b)	Changes in Internal Controls

There were no changes in the Company's internal ~~controls~~control over financial reporting, other than those stated below, identified in connection with the evaluation required by paragraph (d) of the Exchange Act Rules 13a-15 or 15d-15 that occurred during the quarter ended ~~September 29, 2012~~March 30, 2013 that materially affected, or were reasonably likely to materially affect, the Company's internal control over financial reporting.

Subsequent Remediation Efforts

The following remediation efforts, as outlined below, were designed to address the aforementioned material weakness identified by management and to strengthen our internal control over financial reporting.

In response to the identification of the material weakness, in the first quarter of 2013 management performed additional procedures designed to ensure the reliability of our financial reporting and based upon such performance we believe the consolidated financial statement included in this report as of and for the periods ended March 30, 2013 are fairly stated in all material respects. Furthermore, in the first quarter of 2013 management (1) has begun implementing appropriate changes to address segregation of duties conflicts and restricted access within the information technology used in our core business and (2) designed new controls or improved existing controls related to vendor and customer master data changes, transaction level controls as well as financial close controls. In addition, we have evaluated staffing levels and modified responsibilities as well as increased training to reinforce pre-established and new controls to improve our ability to detect potential misstatements in our internally prepared reports, analyses and financial records.

PART II

Item 1A. Risk Factors

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December ~~31, 2011,~~29, 2012, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. There have been no material changes to the risk factors set forth in our Annual Report on Form 10-K for the year ended December ~~31, 2011.~~29, 2012.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table provides information relating to the ~~our~~ purchases of shares of our common stock during the quarter ended ~~September 29, 2012~~March 30, 2013.

Total Number
of Shares
Purchased

Average
Price Paid
per Share

Total Number of
Shares Purchased
as Part of Publicly
Announced Plans
or Programs

Approximate Dollar
Value of Shares
That May Yet Be
Purchased Under
the Plans or
Programs
July 1, 2012 to July 28, 2012 113,621
$ 33.00
113,592
$ 84,713
July 29, 2012 to August 25, 2012 131,388
$ 36.27
131,388
$ 79,948
August 26, 2012 to September 29, 2012 170,998
$ 37.95
170,998
$ 73,458
Total: 416,007

415,978



	Total Number of Shares Purchased	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs
December 30, 2012 to January 26, 2013	44,527	$	40.43	44,527	$	53,016
January 27, 2013 to February 23, 2013	110,225	$	41.35	110,225	$	48,458
February 24, 2013 to March 30, 2013	114,046	$	40.08	2,531	$	48,358
Total:	268,798			157,283

On July 29, 2010, our Board of Directors authorized a $500.0 million stock repurchase program. Our Board of Directors increased the stock repurchase authorization by $250.0 million to $750.0 million on October 20, 2010.

During the ~~third~~first quarter of ~~2012~~2013, we repurchased ~~415,978~~157,283 shares of common stock for ~~$15.0~~6.5 million under our Rule 10b5-1 ~~and 10b5-18~~ Purchase Plan and in open market trading.

Additionally, the Company's Incentive Plans permit the netting of common stock upon vesting of restricted stock awards in order to satisfy individual tax withholding requirements. Accordingly, during the ~~quarter~~period ended ~~September 29, 2012~~March 30, 2013, we acquired ~~749~~111,515 shares for a nominal amount as a result of such withholdings.

3532

Item 6. Exhibits

(a) Exhibits

10.1 Certificate of Insurance for Life Insurance for Dr. Jorg Geller dated February 8, 1988.

10.2 Certificate if Insurance for Life Insurance for Dr. Jorg Geller dated April 24, 1998.


10.3	Provision Committed by Charles River Wiga Deutschland Gmbh for Dr. Jorg Geller dated December 13, 1996.


10.4	Adendum to Provision Commitment by Charles River Wiga Deutschland Gmbh for Dr. Jorg Geller dated March 25, 1997.


21.1	Subsidiaries of Charles River Laboratories, International, Inc.

31.1 Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer. Filed herewith.

31.2 Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer. Filed herewith.


32.1	Certification of the Principal Executive Officer and the Principal Financial Officer required by Rule 13a-14(a) of 15d-14(a) of the Exchange Act. Filed herewith.

101

The following materials from the Form 10-Q for the year period ended ~~September 29, 2012~~March 30, 2013 formatted in XBRL (eXtensible Business Reporting Language): (i) the Condensed Consolidated Statements of Operations, (ii) the Condensed Consolidated Statements of Comprehensive Income , (iii) the Condensed Consolidated Balance Sheets, (iv) the Condensed Consolidated Statements of Shareholders' Equity, (v) the Condensed Consolidated Statements of Cash Flows, and (vi) related notes to these Unaudited, Condensed Consolidated Interim Financial Statements.

3633

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



		CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
	~~November 1, 2012~~May 8, 2013	/s/ JAMES C. FOSTER
		James C. Foster Chairman, President and Chief Executive Officer



	~~November 1, 2012~~May 8, 2013	/s/ THOMAS F. ACKERMAN
		Thomas F. Ackerman Corporate Executive Vice President and Chief Financial Officer ~~and Principal Accounting Officer~~

Exhibit 31.1

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES‑OXLEY ACT OF 2002

AND RULE 13a-14(a)/15d-14(a) OF THE EXCHANGE ACT OF 1934

I, James C. Foster, Chief Executive Officer of Charles River Laboratories International, Inc. (the registrant) certify that:


1.	I have reviewed this quarterly report on Form 10-Q for the quarter ended March 30, 2013 of the registrant;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


4.	The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


a.	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


b.	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


c.	evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and


d.	disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and


5.	The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):


a.	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and


b.	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.



Dated: May 8, 2013	/s/ James C. Foster James C. Foster Chairman, President and Chief Executive Officer Charles River Laboratories International, Inc.

Exhibit 31.2

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES‑OXLEY ACT OF 2002

AND RULE 13a-14(a)/15d-14(a) OF THE EXCHANGE ACT OF 1934

I, Thomas F. Ackerman, Corporate Executive Vice President and Chief Financial Officer of Charles River Laboratories International, Inc. (the registrant) certify that:


1.	I have reviewed this quarterly report on Form 10-Q for the quarter ended March 30, 2013 of the registrant;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


4.	The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


a.	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


b.	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


c.	evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and


d.	disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and


5.	The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):


a.	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and


b.	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.



Dated: May 8, 2013	/s/ Thomas F. Ackerman Thomas F. Ackerman Corporate Executive Vice President and Chief Financial Officer Charles River Laboratories International, Inc.

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES‑OXLEY ACT OF 2002

In connection with the quarterly report on Form 10-Q for the quarter ended March 30, 2013 of Charles River Laboratories International, Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, James C. Foster, Chairman, Chief Executive Officer and President of the Company, and Thomas F. Ackerman, Corporate Executive Vice President and Chief Financial Officer of the Company, each hereby certifies, to the best of his knowledge and pursuant to 18 U.S.C. Section 1350, that:


(1)	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”); and


(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Dated: May 8, 2013	/s/ James C. Foster James C. Foster Chairman, President and Chief Executive Officer Charles River Laboratories International, Inc.
Dated: May 8, 2013	/s/ Thomas F. Ackerman Thomas F. Ackerman Corporate Executive Vice President and Chief Financial Officer Charles River Laboratories International, Inc.

This certification shall not be deemed “filed” for any purpose, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act.



Twelve Months Ending
September 2013	$	128,757
September 2014	43,142
September 2015	58,830
September 2016	448,561
September 2017	—
Total	$	679,290



	Restricted Stock		Weighted Average Grant Date Fair Value
Outstanding as of December 31, 2011	703,011		$	35.70
Granted	541,820		36.10
Vested	(286,344	)	35.96
Canceled	(16,614	)	35.48
Outstanding as of September 29, 2012	941,873		$	35.85



Current assets (excluding cash)	$	2,189
Property, plant and equipment	549
Current liabilities	(1,084		)
Long term liabilities	(3,572		)
Goodwill and other finite-lived intangible assets	18,820
Total purchase price allocation	$	16,902



			Weighted average amortization life (in years)
Client relationships	$	1,600	13
Proprietary database	3,900		11
Standard operating procedures	2,500		4
Trademarks and trade names	300		12
Goodwill	$	10,520
Total goodwill and other intangible assets	$	18,820